Abilify (Aripiprazole) Patient Information

See Abilify's Full Prescribing Information

ABILIFY® MEDICATION GUIDE

ABILIFY (a BIL ĭ fī) (aripiprazole) Tablets

ABILIFY® (a BIL ĭ fī) (aripiprazole) Orally Disintegrating Tablets

ABILIFY® (a BIL ĭ fī) (aripiprazole) Oral Solution

ABILIFY® (a BIL ĭ fī) (aripiprazole) Injection, for intramuscular use

IMPORTANT SAFETY INFORMATION and INDICATIONS for ABILIFY®(aripiprazole)

Elderly people with psychosis related to dementia (for example, an inability to perform daily activities as a result of increased memory loss), treated with antipsychotic medicines including ABILIFY, are at an increased risk of death compared to placebo. ABILIFY is not approved for the treatment of people with dementia-related psychosis.

Antidepressant medicines may increase suicidal thoughts or behaviors in some children, teenagers, and young adults, especially within the first few months of treatment or when the dose is changed. Depression and other serious mental illnesses are themselves associated with an increase in the risk of suicide. Patients on antidepressants and their families or caregivers should watch for new or worsening depression symptoms, unusual changes in behavior, or thoughts of suicide. Such symptoms should be reported to the patient’s healthcare provider right away, especially if they are severe or occur suddenly. ABILIFY is not approved for use in pediatric patients with depression.

Some people taking ABILIFY have had unusual urges, such as gambling, binge eating or eating that you cannot control (compulsive), compulsive shopping and sexual urges.

Do not take ABILIFY if you are allergic to aripiprazole or any of the ingredients in ABILIFY. Allergic reactions have ranged from rash, hives, and itching to anaphylaxis, which may include difficulty breathing, tightness in the chest, and swelling of the mouth, face, lips, or tongue.

What is the most important information I should know about ABILIFY?

(For other side effects, also see “What are the possible side effects of ABILIFY?” located within this article)

Serious side effects may happen when you take ABILIFY, including:

Increased risk of death in elderly patients with dementia-related psychosis:

  • Medicines like ABILIFY can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). ABILIFY is not approved for the treatment of patients with dementia-related psychosis.

Risk of suicidal thoughts or actions:

  • Antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions.
  • Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.

Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions.

How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?

Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.

Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.

Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.

Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:

  • thoughts about suicide or dying
  • attempts to commit suicide
  • new or worse depression
  • new or worse anxiety
  • feeling very agitated or restless
  • panic attacks
  • trouble sleeping (insomnia)
  • new or worse irritability
  • acting aggressive, being angry, or violent
  • acting on dangerous impulses
  • an extreme increase in activity and talking (mania)
  • other unusual changes in behavior or mood

What else do I need to know about antidepressant medicines?

Never stop an antidepressant medicine without first talking to a healthcare provider. Stopping an antidepressant medicine suddenly can cause other symptoms.

Antidepressants are medicines used to treat depression and other illnesses. It is important to discuss all the risks of treating depression and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.

Antidepressant medicines have other side effects. Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.

Antidepressant medicines can interact with other medicines. Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.

Not all antidepressant medicines prescribed for children are FDA approved for use in children. Talk to your child’s healthcare provider for more information.

What is ABILIFY?

ABILIFY Oral Tablets, Orally-Disintegrating Tablets, and Oral Solution are prescription medicines used to treat:

  • schizophrenia
  • manic or mixed episodes that happen with bipolar I disorder
  • major depressive disorder (MDD) when ABILIFY is used with antidepressant medicines
  • irritability associated with autistic disorder
  • Tourette’s disorder

ABILIFY Injection is a prescription medicine used to treat: agitation associated with schizophrenia or bipolar mania. It is not known if ABILIFY is safe or effective in children:

  • under 13 years of age with schizophrenia
  • under 10 years of age with bipolar I disorder
  • under 6 years of age with irritability associated with autistic disorder
  • under 6 years of age with Tourette’s disorder

Do not take ABILIFY if you are allergic to aripiprazole or any of the ingredients in ABILIFY. See the end of this Medication Guide for a complete list of ingredients in ABILIFY.

Before taking ABILIFY, tell your healthcare provider about all your medical conditions, including if you have or had:

  • diabetes or high blood sugar in you or your family; your healthcare provider should check your blood sugar before you start ABILIFY and also during therapy.
  • seizures (convulsions).
  • low or high blood pressure.
  • heart problems or stroke.
  • pregnancy or plans to become pregnant.

It is not known if ABILIFY will harm your unborn baby. If you become pregnant while receiving ABILIFY, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or go to http://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/

  • breast-feeding or plans to breastfeed. ABILIFY passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive ABILIFY.
  • low white blood cell count.
  • phenylketonuria. ABILIFY DISCMELT Orally Disintegrating Tablets contain phenylalanine.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

ABILIFY and other medicines may affect each other causing possible serious side effects.

ABILIFY may affect the way other medicines work, and other medicines may affect how ABILIFY works. Your healthcare provider can tell you if it is safe to take ABILIFY with your other medicines.

Do not start or stop any medicines while taking ABILIFY without talking to your healthcare provider first.

Know the medicines you take. Keep a list of your medicines to show your healthcare provider and pharmacist when you get a new medicine.

How should I take ABILIFY?

  • Take ABILIFY exactly as your healthcare provider tells you to take it. Do not change the dose or stop taking ABILIFY yourself.
  • ABILIFY can be taken with or without food.
  • ABILIFY tablets should be swallowed whole.
  • If you miss a dose of ABILIFY, take the missed dose as soon as you remember. If it is almost time for the next dose, just skip the missed dose and take your next dose at the regular time. Do not take two doses of ABILIFY at the same time.
  • If you have been prescribed ABILIFY DISCMELT, take it as follows:
  • Do not open the blister until ready to take the DISCMELT tablet.
  • To remove one DISCMELT tablet, open the package and peel back the foil on the blister to expose the tablet.
  • Do not push the tablet through the foil because this could damage the tablet.
  • Immediately upon opening the blister, using dry hands, remove the tablet and place the entire ABILIFY DISCMELT Orally Disintegrating Tablet on the tongue.
  • Tablet disintegration occurs rapidly in saliva. It is recommended that ABILIFY DISCMELT be taken without liquid. However, if needed, it can be taken with liquid.
  • Do not attempt to split the DISCMELT tablet.

If you take too much ABILIFY, call your healthcare provider or poison control center at 1-800-2221222 right away, or go to the nearest hospital emergency room.

What should I avoid while taking ABILIFY?

  • Do not drive, operate heavy machinery, or do other dangerous activities until you know how ABILIFY affects you. ABILIFY may make you drowsy.
  • Avoid getting overheated or dehydrated.
  • Do not over-exercise.
  • In hot weather, stay inside in a cool place if possible.
  • Stay out of the sun. Do not wear too much or heavy clothing.
  • Drink plenty of water.

What are the possible side effects of ABILIFY?

Also see “What is the most important information I should know about ABILIFY?” earlier in this Medication Guide

ABILIFY may cause serious side effects, including:

  • Stroke in elderly people (cerebrovascular problems) that can lead to death
  • Neuroleptic malignant syndrome (NMS). Tell your healthcare provider right away if you have some or all of the following symptoms: high fever, stiff muscles, confusion, sweating, changes in pulse, heart rate, and blood pressure. These may be symptoms of a rare and serious condition that can lead to death. Call your healthcare provider right away if you have any of these symptoms.
  • Uncontrolled body movements (tardive dyskinesia). ABILIFY may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop receiving ABILIFY. Tardive dyskinesia may also start after you stop receiving ABILIFY.
  • Problems with your metabolism such as high blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who take ABILIFY. Extremely high blood sugar can lead to coma or death. If you have diabetes or risk factors for diabetes (such as being overweight or a family history of diabetes), your healthcare provider should check your blood sugar before you start ABILIFY and during your treatment.
  • Call your healthcare provider if you have any of these symptoms of high blood sugar while receiving ABILIFY:
    • feel very thirsty
    • need to urinate more than usual
    • feel very hungry
    • feel weak or tired
    • feel sick to your stomach
    • feel confused, or your breath smells fruity
    • Increased fat levels (cholesterol and triglycerides) in your blood.
    • Weight gain. You and your healthcare provider should check your weight regularly.
  • Unusual urges. Some people taking ABILIFY have had unusual urges, such as gambling, binge eating or eating that you cannot control (compulsive), compulsive shopping and sexual urges. If you or your family members notice that you are having unusual urges or behaviors, talk to your healthcare provider.
  • Orthostatic hypotension (decreased blood pressure). Lightheadedness or fainting may happen when rising too quickly from a sitting or lying position.
  • Falls. ABILIFY may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries.
  • Low white blood cell count
  • Seizures (convulsions)
  • Problems with control of your body temperature especially when you exercise a lot or are in an area that is very hot. It is important for you to drink water to avoid dehydration. See “What should I avoid while receiving ABILIFY?”
  • Difficulty swallowing that can cause food or liquid to get into your lungs.

The most common side effects of ABILIFY in adults include:

  • nausea
  • dizziness
  • vomiting
  • anxiety
  • constipation
  • insomnia
  • headache
  • restlessness
  • blurred vision
  • upper respiratory illness
  • inner sense of restlessness/need to move (akathisia)

The most common side effects of ABILIFY in children include:

  • feeling sleepy
  • insomnia
  • headache
  • nausea
  • vomiting
  • stuffy nose
  • fatigue
  • weight gain
  • increased or decreased appetite
  • uncontrolled movement such as restlessness, tremor
  • increased saliva or drooling
  • muscle stiffness

These are not all the possible side effects of ABILIFY. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA1088.

How should I store ABILIFY?

Store ABILIFY at room temperature, between 68°F to 77°F (20°C to 25°C).

Opened bottles of ABILIFY Oral Solution can be used for up to 6 months after opening, but not beyond the expiration date on the bottle.

Keep ABILIFY and all medicines out of the reach of children.

General information about the safe and effective use of ABILIFY

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.

Do not use ABILIFY for a condition for which it was not prescribed.

Do not give ABILIFY to other people, even if they have the same symptoms you have. It may harm them.

You can ask your healthcare provider or pharmacist for information about ABILIFY that was written for healthcare professionals.

What are the ingredients in ABILIFY?

Active ingredient: aripiprazole

Inactive ingredients:

Tablets: cornstarch, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. Colorants include ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum Lake

ABILIFY DISCMELT Orally Disintegrating Tablets: acesulfame potassium, aspartame (which contains phenylalanine), calcium silicate, croscarmellose sodium, crospovidone, crème de vanilla (natural and artificial flavors), magnesium stearate, microcrystalline cellulose, silicon dioxide, tartaric acid, and xylitol. Colorants include ferric oxide (yellow or red) and FD&C Blue No. 2 Aluminum Lake

ABILIFY Oral Solution: disodium edetate, fructose (200 mg per mL), glycerin, dl-lactic acid, methylparaben, propylene glycol, propylparaben, sodium hydroxide, sucrose (400 mg per mL), and purified water. The oral solution is flavored with natural orange cream and other natural flavors

For more information about ABILIFY go to www.abilify.com or call 1-800-438-6055.

See Abilify's Full Prescribing Information

Tablets manufactured by Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan

Orally Disintegrating Tablets, Oral Solution, and Injection manufactured by Bristol-Myers Squibb Company, Princeton, NJ 08543 USA

Distributed and marketed by Otsuka America Pharmaceutical, Inc., Rockville, MD 20850

USA ABILIFY is a trademark of Otsuka Pharmaceutical Company.

© Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan

This Medication Guide has been approved by the U.S. Food and Drug Administration Revised: 06/2020 03US20IBR0006

APA Reference
Staff, H. (2009, January 3). Abilify (Aripiprazole) Patient Information, HealthyPlace. Retrieved on 2024, September 27 from https://www.healthyplace.com/other-info/psychiatric-medications/abilify-aripiprazole-patient-information

Last Updated: April 26, 2023

Psychiatric Medications

Detailed overview of psychiatric medications. Antidepressant and antianxiety medications, bipolar medications, antipsychotic drugs.

Mental illnesses are among the most common conditions affecting health today: One in five American adults suffers a diagnosable mental illness in any six month period. According to the National Institute of Mental Health, though, some 90 percent of these people will improve or recover if they get treatment. Psychiatrists and other physicians treating mental illnesses have a wide variety of treatments available today to help them help their patients. Most often, psychiatrists will work with a new patient to construct a treatment plan that includes both psychotherapy and a psychiatric medication. These medications--combined with other treatments such as individual psychotherapy, group therapy, behavioral therapy or self-help groups--help millions each year to return to normal, productive lives in their communities, living at home with loved ones and continuing their work.

Mental Illnesses and Medications

Psychiatric researchers believe that people suffering from many mental illnesses have imbalances in the way their brain metabolizes certain chemicals, called neurotransmitters. Because neurotransmitters are the messengers the nerve cells use to communicate with one another, these imbalances may result in the emotional, physical and intellectual problems that mentally ill people suffer. New knowledge about how the brain functions has permitted psychiatric researchers to develop medications which can alter the way in which the brain produces, stores and releases these neurotransmitter chemicals, alleviating the symptoms of the illness.

Find out about specific psychiatric medications

Psychiatric Medications

Psychiatric medications are like any other medicine your doctor would prescribe. They are formulated to treat specific conditions, and they must be monitored by a physician, such as a psychiatrist, who is skilled in treating your illness. Like most medications, psychiatric prescriptions may take a few days or a few weeks to become fully effective.

All medicines have positive and negative effects. Antibiotics, which cure potentially serious bacterial infections, can cause nausea. Heart disease medication can cause low blood pressure. Even over-the-counter drugs such as cold remedies can cause drowsiness, while aspirin can cause stomach problems, bleeding and allergic reactions. The same principle applies to psychiatric medications. While very effective in controlling the painful emotional and mental symptoms, psychiatric medicines can produce unwanted side effects. People suffering from mental illness should work closely with their physicians to understand what medicines they are taking, why they are taking them, how to take them and what side effects to watch for.

Before deciding whether or not to prescribe psychiatric medication, psychiatrists either conduct or order a thorough psychological and medical evaluation which may include laboratory tests. After a patient has begun taking a medication, the psychiatrist closely monitors his or her patient's health throughout the time the patient is taking the medicine. Often, the side effects disappear after several days on the medication; if they don't, the psychiatrist may change the dose or switch to another medicine that maintains the benefits but reduces the side effects. The psychiatrist may also prescribe a different medicine if the first one does not alleviate symptoms within a reasonable period of time.

Classes of Medications

Antidepressant medications

Depression, which afflicts 9.4 million Americans in any six-month period, is the most common form of mental illness. Far different from the normal mood shifts everyone feels on occasion, depression causes a profound and unremitting sense of sadness, hopelessness, helplessness, guilt and fatigue. People suffering from depression find no happiness or joy in activities once enjoyed or in being with family and friends. They may be irritable and develop sleeping and eating problems. Unrecognized and untreated, depression can kill, as its victims are at high risk for suicide.

However, up to 80 percent of people suffering from major depressive disorder, bipolar disorder, and other forms of this illness respond very well to treatment. Generally, treatment will include some form of psychotherapy and, often, a medication that relieves the excruciating symptoms of depression. Because people suffering from depression are likely to suffer from a relapse, psychiatrists may prescribe antidepressant medications for six months or longer, even if the symptoms disappear.

Types of antidepressant medication

Three classes of medication are used as antidepressants: heterocyclic antidepressants (formerly called tricyclics), monoamine oxidase inhibitors (MAOIs) and serotonin-specific agents. A fourth medication--the mineral salt lithium--works with bipolar disorder. The benzodiazepine alprazolam is sometimes also used with depressed patients who also have an anxiety disorder.

Taken as prescribed, these medications can mean the difference between life and death for many patients. Antidepressant medications alleviate the terrible emotional suffering and give people a chance to benefit from the non-drug therapies that enable them to deal with the psychological issues that may also be part of their depression.

Heterocyclic (Tricyclic) Antidepressants: This group of antidepressants comprises amitriptyline, amoxapine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, protriptyline, and trimipramine. They are safe and effective for up to 80 percent of all people with depression who take them.

At first, heterocyclics may cause blurred vision, constipation, a feeling of light-headedness when standing or sitting up suddenly, a dry mouth, retention of urine or feelings of confusion. A small percentage of people will have other side effects such as sweating, a racing heartbeat, low blood pressure, allergic skin reactions or sensitivity to the sun. Though bothersome, these side effects can be lessened with practical suggestions such as increasing fiber in the diet, sipping water, and getting up from a seat more slowly. They generally disappear after a few weeks, when the therapeutic effects of the medication take hold.

More serious side effects are extremely rare. However, a very small percentage of people being treated with these medications have the aggravation of narrow-angle glaucoma and seizures.

As the bothersome side effects clear, the positive benefits of these medications take hold. Gradually insomnia clears up and energy returns. The person's self-esteem improves and the feelings of hopelessness, helplessness and sadness ease.

MAOIs: Though they are as effective as heterocyclic medications, MAOIs such as isocarboxazid, phenelzine, and tranylcypromine, are prescribed less frequently due to dietary restrictions their use requires. Psychiatrists will sometimes turn to these medications when a person hasn't responded to other antidepressants. MAOIs also help depressed people whose health conditions--such as heart problems or glaucoma--prevent them from taking other types of medications.

People who take MAOIs should not eat foods such as cheese, beans, coffee, chocolate or other items that contain the amino acid tyramine. This amino acid interacts with MAOIs and causes a severe and life-threatening increase in blood pressure. MAOIs also interact with decongestants and several prescription medications. People using these antidepressants should always consult their physicians before taking any other drug, and should rigorously follow dietary instructions.

Serotonin-specific agents: Serotonin-specific medicines--such as fluoxetine and sertraline--represent the newest class of medication for people suffering from depression. These medications have less effect on the cardiovascular system and therefore are helpful for depressed people who have suffered a stroke or heart disease. They generally have fewer side effects than other classes of antidepressants.

However, during the first few days of taking them, patients may feel anxious or nervous, and may suffer sleep disturbances, stomach cramps, nausea, skin rash and, rarely, sleepiness. In extremely rare cases, a person may develop a seizure.

A few patients reported that, though they had no suicidal thoughts before taking fluoxetine, they developed a preoccupation with suicide after medication began. There have also been some reports that very few patients developed violent behavior after beginning to take fluoxetine. Scientific data do not support these claims, however. No studies have shown that the medication itself caused these preoccupations or behaviors, which are also symptoms of depression.

Bipolar medications

People suffering from bipolar disorder go through phases of severe depression that alternate with periods of feeling normal and/or periods of excessive excitement and activity known as mania. During the manic phase, people have extremely high energy, develop grandiose and unrealistic ideas about their abilities, and commit themselves to unrealistic projects. They may go on spending sprees, for example, buying several luxury cars despite moderate income. They may go for days without sleeping. Their thoughts become increasingly chaotic; they speak rapidly and they may become quite angry if interrupted.

Lithium: The medication of first choice for bipolar illness is lithium, which treats both the manic symptoms in seven to ten days and reduces depressive symptoms when they may develop.

Though it is very effective in controlling the wild thoughts and behaviors of mania, lithium does have some side effects, including tremor, weight gain, nausea, mild diarrhea, and skin rashes. People taking lithium should drink 10 to 12 glasses of water a day to avoid dehydration. Adverse reactions which may develop in a small number of people include confusion, slurred speech, extreme fatigue or excitement, muscle weakness, dizziness, difficulty in walking or sleep disturbances.

Physicians also sometimes prescribe anticonvulsant drugs such as carbamazepine or valproate for people with bipolar disorder, though the FDA has not yet approved them for this purpose. It has been known to cause potentially serious blood disorders in a minority of cases.

Antianxiety medications

Anxiety disorders, in addition to generalized anxiety, include such disorders as phobias, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder. Studies indicate that eight percent of all adults have suffered from a phobia, panic disorder or other anxiety disorder during the preceding six months. For millions of Americans, anxiety disorders are disruptive, debilitating and often the reason for loss of job and serious problems in family relationships.

Often an anxiety disorder, such as a simple phobia or post-traumatic stress disorder, responds well to psychotherapy, support groups and other non-medication treatments. But in severe cases, or with certain diagnoses, a person may require medicine to control the unrelenting and uncontrollable tension and fear that rule their lives.

Psychiatrists can prescribe highly effective medications that relieve the fear, help end the physical symptoms such as pounding heart and shortness of breath, and give people a greater sense of control. Psychiatrists often prescribe one of the benzodiazepines, a group of tranquilizers that can reduce debilitating symptoms and enable a person to concentrate on coping with his or her illness. With a greater sense of control, this person can learn how to reduce the stress that can trigger anxiety, developing new behaviors that will lessen the effects of the anxiety disorder.

Benzodiazepines, such as chlordiazepoxide, and diazepam, and several other medications effectively treat mild to moderate anxiety, but these medications should be taken for short periods. Side effects can include drowsiness, impaired coordination, muscular weakness and impaired memory and concentration, and dependence after long-term use.


Alprazolam, which is a high-potency benzodiazepine, is effective against anxiety disorders that are complicated by depression. People with this combination of symptoms who begin treatment may find that their anxiety symptoms worsen when they begin antidepressant medication. Alprazolam helps control those anxiety problems until the antidepressant takes effect. Though alprazolam works quickly and has fewer side effects than antidepressants, it is rarely the medication of first choice because it has a high potential for dependency. Its side effects include drowsiness, impaired coordination, impaired memory and concentration, and muscular weakness.

Another antianxiety medication, buspirone, has different side effects than those sometimes caused by benzodiazepines. Though it has little potential for dependency and doesn't cause drowsiness or impair coordination or memory, buspirone can cause insomnia, nervousness, light-headedness, upset stomach, nausea, diarrhea, and headaches.

Medications for Obsessive-Compulsive Disorder

Obsessive-compulsive disorder -- which causes repeated, unwanted and often very disturbing thoughts and compels repetition of certain ritualistic behaviors -- is a painful and debilitating mental illness. A person with obsessive-compulsive disorder might, for instance, develop a fear of germs that compels him or her to wash his or her hands so often that they continually bleed.

Though obsessive-compulsive disorders are officially classified as anxiety disorders, they respond best to antidepressant medications. In February 1990, the U.S. Food and Drug Administration (FDA) approved clomipramine, a heterocyclic antidepressant, for use against obsessive-compulsive disorder. This medicine acts on serotonin, a neurotransmitter thought to affect mood and alertness. Though this medicine may not take full effect for two or three weeks, it is effective in reducing the uncontrollable thoughts and behaviors and the devastating disruptions they cause in a person's life.

Clomipramine's side effects, like those of all heterocyclic antidepressants, may include drowsiness, hand tremors, dry mouth, dizziness, constipation, headache, insomnia.

While its use in treating anxiety disorders has not yet been approved by the FDA, fluoxetine has shown some promise in research.

Anti-Panic Medications

Like other anxiety illnesses, panic disorder has both physical and mental symptoms. People suffering from a panic attack often think they are having a heart attack: their heart pounds; their chest is tight; they sweat profusely, feel they are choking or smothering, have numbness or tingling around their lips or their fingers and toes, and may be nauseated and chilled. Panic attacks are so terrifying and unpredictable that many victims may begin to avoid places and situations that remind them of those under which previous panic attacks occurred. Over time the victim may even refuse to leave home.

Currently, many psychiatrists may prescribe alprazolam for people who suffer with panic attacks. However, as already stated, this medication can cause dependency when used for an extended period. Once an antidepressant has taken effect, physicians treating panic with alprazolam and an antidepressant in tandem will usually reduce the alprazolam dosage slowly.

Learning new ways of thinking, modifying behavior, learning relaxation techniques and participating in support groups are among the non-medication treatments that are also important parts of the overall treatment plan for panic disorder.

While alprazolam is the only medication the FDA has approved for treatment of panic disorder, research continues into the positive effects of other medications as well.

In clinical trials panic disorder has responded well to heterocyclic antidepressant medications. In fact, antidepressant medications such as imipramine have been effective in reducing panic symptoms in 50 to 90 percent of the patients studied. When combined with psychological and behavioral treatments, the effectiveness of the medications increases. When the panic symptoms lessen, the patient can begin working with the psychiatrist in understanding his or her illness and coping with its effects on daily life.

Likewise, studies have suggested that MAOIs such as phenelzine or tranylcypromine can be as effective as heterocyclic antidepressants in the treatment of panic.

Fluoxetine, which is also awaiting FDA approval for treatment of panic, has had promising results in tests of its effects on panic.

Antipsychotic Drugs

Psychosis is a symptom, not a disease. It can be part of several mental illnesses, such as schizophrenia, bipolar disorder, or major depression. It also can be a symptom of physical illnesses such as brain tumors, or of drug interactions, of substance abuse, or of other physical conditions.

Psychosis alters a person's ability to test reality. A person may suffer from hallucinations, which are sensations that he or she thinks are real but don't exist; delusions, which are ideas which he or she believes despite all proof that they are false; and thought disorders, in which his or her thought processes are chaotic and illogical.

Schizophrenia is the mental illness most often associated with psychosis. Researchers do not know the specific causes of schizophrenia, though most believe that it is primarily a physical brain disease. Some believe that the neurotransmitter dopamine is involved with the hallucinations, delusions, thought disorders and blunted emotional responses of this mental illness. Most medications prescribed for schizophrenia affect the dopamine levels in the brain at the same time they reduce the extremely painful mental and emotional symptoms.


Antipsychotic medications--acetophenazine, chlorpromazine, chlorprothixene, clozapine, fluphenazine, haloperidol, loxapine, mesoridazine, molindone, perphenazine, pimozide, piperacetazine, trifluoperazine, triflupromazine, thioridazine, and thiothixene--lessen the psychotic symptoms and allow the person to participate more fully in life.

Antipsychotic medications do have side effects. They include dry mouth, blurred vision, constipation, and drowsiness. Some people taking the medications can experience a difficulty in urinating that ranges from mild problems beginning urination to complete inability to do so, a condition that requires prompt medical attention.

For many, these side effects lessen over several weeks as their bodies adapt to the medication. To lessen constipation, people taking antipsychotic medications can eat more fruits and vegetables, and drink at least eight glasses of water per day.

Other side effects include greater risk for sunburn, changes in white blood cell count (with clozapine), low blood pressure when standing or sitting up, akathisia, dystonia, parkinsonism, and tardive dyskinesia.

Patients with akathisia (which to some degree affects up to 75 percent of those treated with antipsychotic medications) feel restless or unable to sit still. While this side effect is difficult to treat, some medications among them propranolol, clonidine, lorazepam and diazepam can help. Those with dystonia (between one and eight percent of patients taking antipsychotic medications) feel painful, tightening spasms of the muscles, particularly those in the face and neck. This side effect is also treatable with other medications including benztropine, trihexyphenidyl, procyclidine, and diphenhydramine that act as antidotes. Parkinsonism is a group of symptoms that resemble those brought on by Parkinson's disease, including loss of facial expression, slowed movements, rigidity in arms and legs, drooling, and/or shuffling gate. It affects up to one third of those taking antipsychotic medications, and is also treatable with the medications mentioned for treatment of dystonia, with the exception of diphenhydramine. -

Tardive dyskinesia is one of the most serious side effects of antipsychotic medications. This condition affects between 20 and 25 percent of persons taking antipsychotic drugs. Tardive dyskinesia causes involuntary muscular movements, and though it can affect any muscle group, it often affects facial muscles. There is no known cure for these involuntary movements (though some drugs, including reserpine and levodopa may help) and tardive dyskinesia may be permanent unless its onset is detected early. Psychiatrists emphasize that patients and their family members should watch closely for any signs of this condition. If it begins to develop, the physician can discontinue the medication.

Clozapine, which the FDA approved for prescription in 1990, now offers hope to patients who, because they suffer from so-called "treatment resistant" schizophrenia, could not be helped before by antipsychotic medications. Though clozapine has not been associated with tardive dyskinesia, this antipsychotic medication does cause a serious side effect in one to two percent of the people who take it. This side effect--a blood disorder called agranulocytosis--is potentially fatal because it means the body has stopped producing the white blood cells vital to its protection from infections. To guard against development of this condition, the medicine's manufacturer requires weekly monitoring of the white blood cell count of each person taking the medication. As a result, use of clozapine and its accompanying monitoring system can be expensive.

Though antipsychotic medications have side effects, they offer benefits that far outweigh the risks. The hallucinations and delusions of psychosis can be so terrifying that some people are willing to endure their side effects for relief from the terrors of the illness. The thought disorders can be so confusing and frightening, they isolate those afflicted with them in a lonely world from which no escape seems possible. Unable to know whether the insects they see crawling on their bodies are real, unable to control the voices that harass and degrade them, unable to express their thoughts so others can understand them, people suffering from psychotic symptoms lose their jobs, their friends and their families. Cast into a hostile world of people who are afraid of or unable to understand their disease, these people often become suicidal.

For comprehensive information on specific psychiatric medications visit the HealthyPlace.com Psychiatric Medications Pharmacology Center here.

Extensive information on Psychiatric Medications Treatment here.

Conclusion

No medication, whether an over-the-counter drug such as aspirin or a carefully prescribed psychiatric medication, is without side effects. But just as relief from the pain and discomfort of a cold is worth the potential side effect, so is the relief from the excruciating and potentially fatal symptoms of mental illnesses. Psychiatrists are trained to carefully weigh the benefits and risks of prescribing these medications.

No one should fear taking a psychiatric medication if he or she has received a complete medical and physical examination and is properly monitored for both the medicine's benefit and side effects. Not only do psychiatric medications offer relief from the terror, loneliness, and sorrow that accompany untreated mental illnesses, but they enable people to take advantage of the psychotherapy (which psychiatrists usually prescribe in tandem with medication), self-help groups, and supportive services available through their psychiatrist. Better, these medications and the other services available through mental health care enable people who have mental illness to enjoy their lives, their families and their work.

Find out about specific psychiatric medications


(c) Copyright 1993 American Psychiatric Association
Produced by the APA Joint Commission on Public Affairs and the Division of Public Affairs. This document contains the text of a pamphlet developed for educational purposes and does not necessarily reflect opinion or policy of the American Psychiatric Association.


Additional Resources

Andreasen, Nancy. The Broken Brain: The Biological Revolution in Psychiatry. New York: Harper and Row, 1984.

Gold, Mark S. The Good News About Depression: Cures and Treatments in the New Age of Psychiatry. New York: Villard Books, 1987.

Gold, Mark S. The Good News About Panic, Anxiety & Phobias. New York: Villard Books, 1989.

Goodwin, Frederick K. Depression and Manic-Depressive Illness in Medicine for the Layman. Bethesda, MD: U.S. Department of Health and Human Services, 1982.

Gorman, Jack M. The Essential Guide to Psychiatric Drugs. New York: St. Martin's Press, 1990.

Greist and Jefferson, Eds. Depression and its Treatment: Help for the Nation's Number One Mental Problem. Washington, DC: American Psychiatric Press, Inc., 1984

Henley, Arthur. Schizophrenia: Current Approaches to a Baffling Problem (pamphlet). New York: Public Affairs Pamphlets, 381 Park Ave. South, NY, 1986.

Moak, Rubin, Stein, Eds. The Over-50 Guide to Psychiatric Medications. Washington, DC: American Psychiatric Press, Inc., 1989.

Sargent, M. Depressive Illnesses: Treatments Bring New Hope. U.S. Department of Health and Human Services (ADM 89-1491), 1989.

Torrey, E. Fuller. Surviving Schizophrenia: A Family Manual. New York: Harper and Row, 1988.

Walsh, Maryellen. Schizophrenia: Straight Talk for Families and Friends. New York: William Morrow and Company, Inc., 1985.

Yudofsky, Hales, and Ferguson, Eds. What You Need to Know About Psychiatric Drugs. New York: Grove Weidenfeld, 1991.

Other Resources

Anxiety Disorders Association of America
(301) 231-9350, (703) 524-7600


 


National Depressive and Manic Depressive Association Merchandise Mart
(312) 939-2442

National Institute of Mental Health Public Information Branch
(301) 443-4536

National Mental Health Association
(703) 684-7722

more on: pharmacology of specific psychiatric medications - use, dosage, side-effects.

back to: Psychiatric Medications Pharmacology Homepage

APA Reference
Staff, H. (2009, January 3). Psychiatric Medications, HealthyPlace. Retrieved on 2024, September 27 from https://www.healthyplace.com/other-info/psychiatric-disorder-definitions/psychiatric-medications

Last Updated: August 12, 2019

Psychiatric Hospitalization

Detailed overview of psychiatric hospitalization. Why psychiatric hospitalization is needed, what to expect, involuntary commitment to a psychiatric hospital and more.

Facts About Psychiatric Hospitalization

Hospitalization for psychiatric illness has undergone revolutionary changes in the last three decades. At mid-century, there were two basic sources of care for people with mental illnesses: a psychiatrist's private office, or a mental hospital. Those who went to the hospital often stayed for many months, even years. The hospital, frequently operated by the state, offered protection from the stresses of living which could be overwhelming for those with severe illness. It also offered protection from self-inflicted harm. But it offered little in the way of treatment. The use of medication as a mainstay of rehabilitative treatment had just begun.

Today people with a mental illness have many treatment options depending upon medical need:

  • 24-hour inpatient care in general hospital psychiatric units,
  • private psychiatric hospitals,
  • state and federal public psychiatric hospitals;
  • Veterans Administration (VA) hospitals;
  • partial hospitalization or day care;
  • residential care; community mental health centers;
  • care in the offices of psychiatrists and other mental health practitioners, and
  • support groups.

In all these settings, health care professionals work very hard to provide care according to a treatment plan developed by each patient's psychiatrist. The goal is to restore maximum independent living as rapidly as possible, using the appropriate level of care for the appropriate illness. Frequently, the family is involved as part of the treatment team.

Today, people turn to psychiatric hospitals for help with a wide range of mental illnesses: families coping with the ravages of addiction; a young mother or a grandfather fighting depression; a girl whose eating disorder has put her life in danger; a young executive who cannot shake compulsions that threaten to take over his life; a once-prominent attorney who is nearly a prisoner in her own home because of phobias and anxiety; a veteran of the Vietnam war who can't seem to get over the pain of his past; a youngster whose uncontrollable and destructive behavior threatens to tear her family apart; a college freshman who is frightened and confused by strange voices and delusions.

When Psychiatric Hospitalization is Needed

A psychiatrist's decision to admit a patient to the hospital depends primarily on the severity of the patient's illness. No one is sent to the hospital who can better be treated in the psychiatrist's office or in another less restrictive setting. The presence or absence of social support--family members or other caretakers--can also figure in the psychiatrist's decision to hospitalize a patient. With sufficient social support, a person who might otherwise require hospitalization can often be cared for at home.

In much the same way a physician decides to hospitalize a person for other medical illnesses, the psychiatrist--who is a medical doctor--evaluates the symptoms to determine a treatment plan and the most appropriate treatment setting.

The procedure for hospital admission for a psychiatric illness resembles that for other illnesses. Often, that means a person's health insurance company may require a pre-admission certification before agreeing to pay for a hospitalization. Working with the psychiatrist, insurance company staff will review a patient's case and decide if it is serious enough to require inpatient care. If so, they will approve admission for a limited hospital stay, then periodically review the patient's progress to determine whether the stay should be extended. If care is denied, the psychiatrist and patient may appeal.

What to Expect in a Psychiatric Hospital

Many psychiatric hospitals and mental health units of general hospitals provide the full range of care, from psychotherapy to medication, from vocational training to social services.

Hospitalization reduces the stresses of responsibility for the patient for a brief time and allows the person to concentrate on recovery. As the crisis lessens and the person is better able to assume the challenge, the mental health care team can help him or her to plan for discharge and the community-based services that will help him or her to continue recuperating while living at home.

People in the hospital receive treatment that follows a plan developed by the psychiatrist. The therapies outlined in that plan may involve a variety of mental health professionals: the psychiatrist, a clinical psychologist, nurses, social workers, activity and rehabilitation therapists and, when necessary, an addiction counselor.

Before psychiatric treatment in any hospital begins, a patient undergoes a complete physical examination to determine the overall state of his or her health. Generally, once treatment begins, patients in the hospital receive individual therapy with a primary therapist, group therapy with peers, and family therapy with spouse, children, parents or other significant people. At the same time, patients often receive one or more psychiatric medicines. During therapy sessions, a patient can develop insights into his or her emotional and mental functioning, learn about his or her illness and its effect on relationships and daily living, and establish healthy ways of responding to the illness and daily stresses that can affect mental health. In addition, patients can receive occupational therapy to develop skills for daily living, activity therapy to learn how to develop healthy social relationships in the community, and drug and alcohol evaluation. Throughout the hospital stay, each patient works with his or her treatment team to put together a plan for continued care after the hospital stay is over.

Residential treatment programs are categorized as either medically based or socially based. In medically-based programs patients receive very structured care, including such services as medically necessary supervision and psychotherapy. In socially based programs patients receive psychotherapy, but also learn how to take advantage of community support systems and increase their independence. For example, under a socially based program, patients learn how to apply for government medical assistance that will enable them to get psychiatric and medical services in the community rather than relying on hospitalization for help.

Residential care can also help patients to learn how to maintain a household, cooperate with other residents and work with social and health agencies to get the services they need. This, in turn, improves their self-esteem and confidence.

Hospital personnel pay careful attention to the physical well being of patients. Hospital physicians and nurses monitor the patient's medications, and, with those patients whose severe illnesses may make them a danger to themselves or other patients, take steps to protect them from injury. This can sometimes mean use of restraints or isolation from other patients, measures that are used to protect, not to punish, and only for very brief periods of time. Hospital personnel also work to be sure each patient understands the importance of good nutrition and knows the dietary restrictions that may be necessary because of his or her medications.

Length of Stay

Today the average length of stay for adults in a psychiatric facility is 12 days. The mental health care team and patient begin planning for discharge on the first day of admission. Because medical research has produced highly effective treatments, people who suffer from mental illness today recover from severe episodes much more quickly than in the past.

Likewise, people who suffer from alcohol and substance abuse no longer routinely stay in residential treatment centers for prolonged periods of time. Most recover with short-term stays that average 10 days, followed by partial hospitalization, outpatient and support group services.

Other Psychiatric Hospitalization Options

Once psychiatric treatment stabilizes a patient's condition, he or she may progress to a less-intensive treatment setting. The psychiatrist may recommend partial hospitalization. This option isn't limited to people who are ending a hospital stay; it also meets the needs of people who live in the community and need a higher level of care without the services of overnight, 24-hour nursing.

Partial hospitalization provides individual and group psychotherapy, social and vocational rehabilitation, occupational therapy, assistance with educational needs, and other services to help patients maintain their abilities to function at home, at work and in social circles. However, because their treatment setting helps them to develop a support network of friends and family that can help monitor their conditions when they are not in the hospital, they can return home at night and on weekends. Partial hospitalization or day treatment works best for people whose symptoms are under control. They enter care directly from the community or after being discharged from 24-hour care.

Partial hospitalization is most effective for patients who are ready for therapy and rehabilitation that can move them comfortably back into the community. It is also less expensive. A full day of partial hospitalization costs, on average, $350--roughly half the cost of 24-hour inpatient treatment, according to Health Care Industries of America, a health care consulting company.

When Children Need Psychiatric Hospital Care

Children and teenagers can have mental illnesses. Some of these illnesses--such as conduct disorder and attention-deficit/hyperactivity disorder--usually emerge during these early years. Youngsters also can suffer with illnesses most people would associate first with adults, such as depression or schizophrenia. And like those of adults, children's illnesses can go into remission or worsen from time to time.

When a child's symptoms become severe, a psychiatrist may recommend hospitalization. The physician will consider several factors in making the recommendation:

  • Whether the child poses an actual or imminent danger to him or herself or others;
  • Whether the child's behavior is bizarre and destructive to the community;
  • Whether the child requires medication that must be closely monitored;
  • Whether the child needs 24-hour care in order to become stabilized;
  • Whether the child has failed to improve in other, less restrictive environments.

As with adults, children receiving inpatient care will have a treatment plan that identifies the therapies and goals unique to each child. The treatment team will work with each child in individual, group and family therapy as well as occupational therapy. Youngsters are also often involved in activity therapy, which teaches social skills, and drug and alcohol evaluation and treatment. In addition, the hospital will provide an academic program.

Because the family is integral to a child's recuperation, the treatment team will work closely with parents or guardians to ensure good communication and understanding about the illness, treatment process and recovery prognosis. Families will learn how to work with their children and cope with the stresses that can develop with a serious or chronic illness.

Involuntary Treatment - Commitment to a Psychiatric Hospital

The National Association of Psychiatric Health Systems reports that about 88 percent of adults treated in its members' hospitals are admitted voluntarily. In many states, people so disabled by their illnesses that they don't fully recognize the need for 24-hour inpatient care and who refuse hospital treatment may be involuntarily admitted to the hospital, but only with the knowledge of the court system and following an examination by a physician.

Commitment procedures vary from state to state. There has been some attempt made to shield mentally ill people from the stigma of public court appearances, and sometimes patients can be too ill to attend a hearing. For these reasons, a mentally ill person may, in some states, be admitted on the advice of one or two physicians who act within a very strict set of procedures to insure full protection of the patient's legal rights. Most states allow a physician to prescribe that a person be admitted involuntarily to a hospital for a brief evaluation period, usually three-days.

During the evaluation period, a team of psychiatrists and mental health professionals can learn whether the person's illness requires longer hospital care or can be managed effectively with less intensive treatment, such as partial hospitalization.

If the evaluation team thinks a patient requires inpatient care past the three-day period, it can request longer admission--a request that, it should be emphasized, is subject to a hearing. At this hearing, the patient or his or her representative must be present. No decisions regarding a patient's hospitalization and subsequent treatment can be made without the presence of the patient or this representative. If involuntary admission is recommended, the court can issue an order for only a specific period of time. At the end of that period, the question of hospitalization must again go to a court hearing.

Involuntary treatment is sometimes necessary, but is used only in unusual circumstances and is always subject to a review which protects the civil liberties of patients.

There if You Need it

If your physician prescribes hospitalization, you, a member of your family, a friend or other advocate should tour the recommended facility and learn about its admissions procedure, daily schedules and the mental health care team with whom you or your family member will be working. Learn how treatment progress will be communicated and what your role will be. This may help you to feel more comfortable about complying with your physician's recommendation. And that comfort can only contribute to the progress you or your loved one will make during hospital care.

Regardless of the illness, it's good to know that a range of health care services are available for patients and their families. Certainly, outpatient care is the most common treatment setting. But when an illness becomes severe, effective hospital services are there to meet the need.


(c) Copyright 1994 American Psychiatric Association

Produced by the APA Joint Commission on Public Affairs and the Division of Public Affairs. This document contains text of a pamphlet developed for educational purposes and does not necessarily reflect opinion or policy of the American Psychiatric Association.


Additional Resources

Dalton, R. and Forman, M. Psychiatric Hospitalization of School-Age Children. Washington, DC: American Psychiatric Press, Inc., 1992.

Consent to Voluntary Hospitalization: Report of the American Psychiatric Association Task Force on Consent to Voluntary Hospitalization. Washington, DC: American Psychiatric Press, Inc., 1992.

Facts for Families Information Sheet Series, "Children's Major Psychiatric Disorders," and "The Continuum of Care." Washington, DC: American Academy of Child and Adolescent Psychiatry, 1994.

Kiesler, C. and Sibulkin, A. Mental Hospitalization: Myths and Facts About A National Crisis. Newbury Park, CA: Sage Publications, 1987.

Korpell, H. How You Can Help: A Guide for Families of Psychiatric Hospital Patients. Washington, DC: American Psychiatric Press, Inc., 1984.

Krizay, J. Partial Hospitalization: Facilities, Cost & Utilization.Washington, DC: The American Psychiatric Association, Inc., 1989.

Policy Statements on Inpatient Hospital Treatment of Children and Adolescents. Washington, DC: American Academy of Child and Adolescent Psychiatry, 1989.

APA Reference
Staff, H. (2009, January 3). Psychiatric Hospitalization, HealthyPlace. Retrieved on 2024, September 27 from https://www.healthyplace.com/other-info/psychiatric-disorder-definitions/psychiatric-hospitalization

Last Updated: October 28, 2019

National Institutes of Health Consensus Development Impotence Conference Statement

male sexual problems

December 7-9, 1992

CONTENTS:

ABSTRACT

INTRODUCTION

Prevalence and Association of Erectile Dysfunction with Age.

Clinical, Psychological, and Social Impact of Erectile Dysfunction.

Physiology of Erection.

Erectile Dysfunction.

Risk Factors of Erectile Dysfunction.

Prevention of Erectile Dysfunction.

Diagnosis of Erectile Dysfunction.

Treatments for Erectile Dysfunction.

Psychotherapy and Behavioral Therapy for Erectile Dysfunction.

Medical Therapy for Erectile Dysfunction.

Intracavernosal Injection Therapy for Erectile Dysfunction.

Vacuum/Constrictive Devices to Treat Erectile Dysfunction

Vascular Surgery to Treat Erectile Dysfunction.

Penile Prostheses to Treat Erectile Dysfunction.

Staging of Erectile Dysfunction Treatment

Improving Knowledge of Erectile Dysfunction.

Strategies for Improving Public Knowledge of Erectile Dysfunction.

Strategies for Improving Professional Knowledge of Erectile Dysfunction.

What are the needs for future erectile dysfunction research?

CONCLUSIONS

 


 



ABSTRACT

The National Institutes of Health Consensus Development Conference on Impotence was convened to address (1) the prevalence and clinical, psychological, and social impact of erectile dysfunction; (2) the risk factors for erectile dysfunction and how they might be used in preventing its development; (3) the need for and appropriate diagnostic assessment and evaluation of patients with erectile dysfunction; (4) the efficacies and risks of behavioral, pharmacological, surgical, and other treatments for erectile dysfunction; (5) strategies for improving public and professional awareness and knowledge of erectile dysfunction; and (6) future directions for research in prevention, diagnosis, and management of erectile dysfunction. Following 2 days of presentations by experts and discussion by the audience, a consensus panel weighed the evidence and prepared their consensus statement.

Among their findings, the panel concluded that (1) the term "erectile dysfunction" should replace the term "impotence"; (2) the likelihood of erectile dysfunction increases with age but is not an inevitable consequence of aging; (3) embarrassment of patients and reluctance of both patients and health care providers to discuss sexual matters candidly contribute to underdiagnosis of erectile dysfunction; (4) many cases of erectile dysfunction can be successfully managed with appropriately selected therapy; (5) the diagnosis and treatment of erectile dysfunction must be specific and responsive to the individual patient's needs and that compliance as well as the desires and expectations of both the patient and partner are important considerations in selecting appropriate therapy; (6) education of health care providers and the public on aspects of human sexuality, sexual dysfunction, and the availability of successful treatments is essential; and (7) erectile dysfunction is an important public health problem deserving of increased support for basic science investigation and applied research.

The full text of the consensus panel's statement follows.


 


INTRODUCTION

 

The term "impotence," as applied to the title of this conference, has traditionally been used to signify the inability of the male to attain and maintain erection of the penis sufficient to permit satisfactory sexual intercourse. However, this use has often led to confusing and uninterpretable results in both clinical and basic science investigations. This, together with its pejorative implications, suggests that the more precise term "erectile dysfunction" be used instead to signify an inability of the male to achieve an erect penis as part of the overall multifaceted process of male sexual function.

This process comprises a variety of physical aspects with important psychological and behavioral overtones. In analyzing the material presented and discussed at this conference, this consensus statement addresses issues of male erectile dysfunction, as implied by the term "impotence." However, it should be recognized that desire, orgasmic capability, and ejaculatory capacity may be intact even in the presence of erectile dysfunction or may be deficient to some extent and contribute to the sense of inadequate sexual function.

Erectile dysfunction affects millions of men. Although for some men erectile function may not be the best or most important measure of sexual satisfaction, for many men erectile dysfunction creates mental stress that affects their interactions with family and associates. Many advances have occurred in both diagnosis and treatment of erectile dysfunction. However, its various aspects remain poorly understood by the general population and by most health care professionals. Lack of a simple definition, failure to delineate precisely the problem being assessed, and the absence of guidelines and parameters to determine assessment and treatment outcome and long-term results, have contributed to this state of affairs by producing misunderstanding, confusion, and ongoing concern. That results have not been communicated effectively to the public has compounded this situation.

Cause-specific assessment and treatment of male sexual dysfunction will require recognition by the public and the medical community that erectile dysfunction is a part of overall male sexual dysfunction. The multifactorial nature of erectile dysfunction, comprising both organic and psychologic aspects, may often require a multidisciplinary approach to its assessment and treatment. This consensus report addresses these issues, not only as isolated health problems but also in the context of societal and individual perceptions and expectations.

Erectile dysfunction is often assumed to be a natural concomitant of the aging process, to be tolerated along with other conditions associated with aging. This assumption may not be entirely correct. For the elderly and for others, erectile dysfunction may occur as a consequence of specific illnesses or of medical treatment for certain illnesses, resulting in fear, loss of image and self-confidence, and depression.

For example, many men with diabetes mellitus may develop erectile dysfunction during their young and middle adult years. Physicians, diabetes educators, and patients and their families are sometimes unaware of this potential complication. Whatever the causal factors, discomfort of patients and health care providers in discussing sexual issues becomes a barrier to pursuing treatment.

Erectile dysfunction can be effectively treated with a variety of methods. Many patients and health care providers are unaware of these treatments, and the dysfunction thus often remains untreated, compounded by its psychological impact. Concurrent with the increase in the availability of effective treatment methods has been increased availability of new diagnostic procedures that may help in the selection of an effective, cause-specific treatment. This conference was designed to explore these issues and to define the state of the art.


To examine what is known about the demographics, etiology, risk factors, pathophysiology, diagnostic assessment, treatments (both generic and cause-specific), and the understanding of their consequences by the public and the medical community, the National Institute of Diabetes and Digestive and Kidney Diseases and the Office of Medical Applications of Research of the National Institutes of Health, in conjunction with the National Institute of Neurological Disorders and Stroke and the National Institute on Aging, convened a consensus development conference on male impotence on December 7-9, 1992. After 1 1/2 days of presentations by experts in the relevant fields involved with male sexual dysfunction and erectile impotence or dysfunction, a consensus panel comprised of representatives from urology, geriatrics, medicine, endocrinology, psychiatry, psychology, nursing, epidemiology, biostatistics, basic sciences, and the public considered the evidence and developed answers to the questions that follow.

WHAT ARE THE PREVALENCE AND CLINICAL, PSYCHOLOGICAL, AND SOCIAL IMPACT OF IMPOTENCE (CULTURAL, GEOGRAPHICAL, NATIONAL, ETHNIC, RACIAL, MALE/FEMALE PERCEPTIONS AND INFLUENCES)?

Prevalence and Association with Age

Estimates of the prevalence of impotence depend on the definition employed for this condition. For the purposes of this consensus development conference statement, impotence is defined as male erectile dysfunction, that is, the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. Erectile performance has been characterized by the degree of dysfunction, and estimates of prevalence (the number of men with the condition) vary depending on the definition of erectile dysfunction used.


 


Appallingly little is known about the prevalence of erectile dysfunction in the United States and how this prevalence varies according to individual characteristics (age, race, ethnicity, socioeconomic status, and concomitant diseases and conditions). Data on erectile dysfunction available from the 1940's applied to the present U.S. male population produce an estimate of erectile dysfunction prevalence of 7 million.

More recent estimates suggest that the number of U.S. men with erectile dysfunction may more likely be near 10-20 million. Inclusion of individuals with partial erectile dysfunction increases the estimate to about 30 million. The majority of these individuals will be older than 65 years of age. The prevalence of erectile dysfunction has been found to be associated with age. A prevalence of about 5 percent is observed at age 40, increasing to 15-25 percent at age 65 and older. One-third of older men receiving medical care at a Department of Veterans' Affairs ambulatory clinic admitted to problems with erectile function.

Causes contributing to erectile dysfunction can be broadly classified into two categories: organic and psychologic. In reality, while the majority of patients with erectile dysfunction are thought to demonstrate an organic component, psychological aspects of self-confidence, anxiety, and partner communication and conflict are often important contributing factors.

The 1985 National Ambulatory Medical Care Survey indicated that there were about 525,000 visits for erectile dysfunction, accounting for 0.2 percent of all male ambulatory care visits. Estimates of visits per 1,000 population increased from about 1.5 for the age group 25-34 to 15.0 for those age 65 and above. The 1985 National Hospital Discharge Survey estimated that more than 30,000 hospital admissions were for erectile dysfunction.

Clinical, Psychological, and Social Impact

Geographic, Racial, Ethnic, Socioeconomic, and Cultural Variation in Erectile Dysfunction. Very little is known about variations in prevalence of erectile dysfunction across geographic, racial, ethnic, socioeconomic, and cultural groups. Anecdotal evidence points to the existence of racial, ethnic, and other cultural diversity in the perceptions and expectation levels for satisfactory sexual functioning. These differences would be expected to be reflected in these groups' reaction to erectile dysfunction, although few data on this issue appear to exist.

One report from a recent community survey concluded that erectile failure was the leading complaint of males attending sex therapy clinics. Other studies have shown that erectile disorders are the primary concern of sex therapy patients in treatment. This is consistent with the view that erectile dysfunction may be associated with depression, loss of self-esteem, poor self-image, increased anxiety or tension with one's sexual partner, and/or fear and anxiety associated with contracting sexually transmitted diseases, including AIDS.

Male/Female Perceptions and Influences. The diagnosis of erectile dysfunction may be understood as the presence of a condition limiting choices for sexual interaction and possibly limiting opportunity for sexual satisfaction. The impact of this condition depends very much on the dynamics of the relationship of the individual and his sexual partner and their expectation of performance. When changes in sexual function are perceived by the individual and his partner as a natural consequence of the aging process, they may modify their sexual behavior to accommodate the condition and maintain sexual satisfaction. Increasingly, men do not perceive erectile dysfunction as a normal part of aging and seek to identify means by which they may return to their previous level and range of sexual activities. Such levels and expectations and desires for future sexual interactions are important aspects of the evaluation of patients presenting with a chief complaint of erectile dysfunction.

In men of all ages, erectile failure may diminish willingness to initiate sexual relationships because of fear of inadequate sexual performance or rejection. Because males, especially older males, are particularly sensitive to the social support of intimate relationships, withdrawal from these relationships because of such fears may have a negative effect on their overall health.


WHAT ARE THE RISK FACTORS CONTRIBUTING TO IMPOTENCE? CAN THESE BE UTILIZED IN PREVENTING DEVELOPMENT OF IMPOTENCE?

Physiology of Erection

The male erectile response is a vascular event initiated by neuronal action and maintained by a complex interplay between vascular and neurological events. In its most common form, it is initiated by a central nervous system event that integrates psychogenic stimuli (perception, desire, etc.) and controls the sympathetic and parasympathetic innervation of the penis. Sensory stimuli from the penis are important in continuing this process and in initiating a reflex arc that may cause erection under proper circumstances and may help to maintain erection during sexual activity.

Parasympathetic input allows erection by relaxation of trabecular smooth muscle and dilation of the helicine arteries of the penis. This leads to expansion of the lacunar spaces and entrapment of blood by compressing venules against the tunica albuginea, a process referred to as the corporal veno- occlusive mechanism. The tunica albuginea must have sufficient stiffness to compress the venules penetrating it so that venous outflow is blocked and sufficient tumescence and rigidity can occur.

Acetylcholine released by the parasympathetic nerves is thought to act primarily on endothelial cells to release a second nonadrenergic-noncholinergic carrier of the signal that relaxes the trabecular smooth muscle. Nitric oxide released by the endothelial cells, and possibly also of neural origin, is currently thought to be the leading of several candidates as this nonadrenergic-noncholinergic transmitter; but this has not yet been conclusively demonstrated to the exclusion of other potentially important substances (e.g., vasoactive intestinal polypeptide). The relaxing effect of nitric oxide on the trabecular smooth muscle may be mediated through its stimulation of guanylate cyclase and the production of cyclic guanosine monophosphate (cGMP), which would then function as a second messenger in this system.


 


Constriction of the trabecular smooth muscle and helicine arteries induced by sympathetic innervation makes the penis flaccid, with blood pressure in the cavernosal sinuses of the penis near venous pressure. Acetylcholine is thought to decrease sympathetic tone. This may be important in a permissive sense for adequate trabecular smooth muscle relaxation and consequent effective action of other mediators in achieving sufficient inflow of blood into the lacunar spaces. When the trabecular smooth muscle relaxes and helicine arteries dilate in response to parasympathetic stimulation and decreased sympathetic tone, increased blood flow fills the cavernous spaces, increasing the pressure within these spaces so that the penis becomes erect. As the venules are compressed against the tunica albuginea, penile pressure approaches arterial pressure, causing rigidity. Once this state is achieved, arterial inflow is reduced to a level that matches venous outflow.

Erectile Dysfunction

Because adequate arterial supply is critical for erection, any disorder that impairs blood flow may be implicated in the etiology of erectile failure. Most of the medical disorders associated with erectile dysfunction appear to affect the arterial system. Some disorders may interfere with the corporal veno-occlusive mechanism and result in failure to trap blood within the penis, or produce leakage such that an erection cannot be maintained or is easily lost.

Damage to the autonomic pathways innervating the penis may eliminate "psychogenic" erection initiated by the central nervous system. Lesions of the somatic nervous pathways may impair reflexogenic erections and may interrupt tactile sensation needed to maintain psychogenic erections. Spinal cord lesions may produce varying degrees of erectile failure depending on the location and completeness of the lesions. Not only do traumatic lesions affect erectile ability, but disorders leading to peripheral neuropathy may impair neuronal innervation of the penis or of the sensory afferents. The endocrine system itself, particularly the production of androgens, appears to play a role in regulating sexual interest, and may also play a role in erectile function.

Psychological processes such as depression, anxiety, and relationship problems can impair erectile functioning by reducing erotic focus or otherwise reducing awareness of sensory experience. This may lead to inability to initiate or maintain an erection. Etiologic factors for erectile disorders may be categorized as neurogenic, vasculogenic, or psychogenic, but they most commonly appear to derive from problems in all three areas acting in concert.

Risk Factors

Little is known about the natural history of erectile dysfunction. This includes information on the age of onset, incidence rates stratified by age, progression of the condition, and frequency of spontaneous recovery. There also are very limited data on associated morbidity and functional impairment. To date, the data are predominantly available for whites, with other racial and ethnic populations represented only in smaller numbers that do not permit analysis of these issues as a function of race or ethnicity.


Erectile dysfunction is clearly a symptom of many conditions, and certain risk factors have been identified, some of which may be amenable to prevention strategies. Diabetes mellitus, hypogonadism in association with a number of endocrinologic conditions, hypertension, vascular disease, high levels of blood cholesterol, low levels of high density lipoprotein, drugs, neurogenic disorders, Peyronie's disease, priapism, depression, alcohol ingestion, lack of sexual knowledge, poor sexual techniques, inadequate interpersonal relationships or their deterioration, and many chronic diseases, especially renal failure and dialysis, have been demonstrated as risk factors. Vascular surgery is also often a risk factor. Age appears to be a strong indirect risk factor in that it is associated with an increased likelihood of direct risk factors. Other factors require more extensive study. Smoking has an adverse effect on erectile function by accentuating the effects of other risk factors such as vascular disease or hypertension. To date, vasectomy has not been associated with an increased risk of erectile dysfunction other than causing an occasional psychological reaction that could then have a psychogenic influence. Accurate risk factor identification and characterization are essential for concerted efforts at prevention of erectile dysfunction.

Prevention

Although erectile dysfunction increases progressively with age, it is not an inevitable consequence of aging. Knowledge of the risk factors can guide prevention strategies. Specific antihypertensive, antidepressant, and antipsychotic drugs can be chosen to lessen the risk of erectile failure. Published lists of prescription drugs that may impair erectile functioning often are based on reports implicating a drug without systematic study. Such studies are needed to confirm the validity of these suggested associations. In the individual patient, the physician can modify the regimen in an effort to resolve the erectile problem.

It is important that physicians and other health care providers treating patients for chronic conditions periodically inquire into the sexual functioning of their patients and be prepared to offer counsel for those who experience erectile difficulties. Lack of sexual knowledge and anxiety about sexual performance are common contributing factors to erectile dysfunction. Education and reassurance may be helpful in preventing the cascade into serious erectile failure in individuals who experience minor erectile difficulty due to medications or common changes in erectile functioning associated with chronic illnesses or with aging.


 


WHAT DIAGNOSTIC INFORMATION SHOULD BE OBTAINED IN ASSESSMENT OF THE IMPOTENT PATIENT? WHAT CRITERIA SHOULD BE EMPLOYED TO DETERMINE WHICH TESTS ARE INDICATED FOR A PARTICULAR PATIENT?

The appropriate evaluation of all men with erectile dysfunction should include a medical and detailed sexual history (including practices and techniques), a physical examination, a psycho-social evaluation, and basic laboratory studies. When available, a multidisciplinary approach to this evaluation may be desirable. In selected patients, further physiologic or invasive studies may be indicated. A sensitive sexual history, including expectations and motivations, should be obtained from the patient (and sexual partner whenever possible) in an interview conducted by an interested physician or another specially trained professional. A written patient questionnaire may be helpful but is not a substitute for the interview. The sexual history is needed to accurately define the patient's specific complaint and to distinguish between true erectile dysfunction, changes in sexual desire, and orgasmic or ejaculatory disturbances. The patient should be asked specifically about perceptions of his erectile dysfunction, including the nature of onset, frequency, quality, and duration of erections; the presence of nocturnal or morning erections; and his ability to achieve sexual satisfaction. Psychosocial factors related to erectile dysfunction should be probed, including specific situational circumstances, performance anxiety, the nature of sexual relationships, details of current sexual techniques, expectations, motivation for treatment, and the presence of specific discord in the patient's relationship with his sexual partner. The sexual partner's own expectations and perceptions should also be sought since they may have important bearing on diagnosis and treatment recommendations.

The general medical history is important in identifying specific risk factors that may account for or contribute to the patient's erectile dysfunction. These include vascular risk factors such as hypertension, diabetes, smoking, coronary artery disease, peripheral vascular disorders, pelvic trauma or surgery, and blood lipid abnormalities. Decreased sexual desire or history suggesting a hypogonadal state could indicate a primary endocrine disorder. Neurologic causes may include a history of diabetes mellitus or alcoholism with associated peripheral neuropathy. Neurologic disorders such as multiple sclerosis, spinal injury, or cerebrovascular accidents are often obvious or well defined prior to presentation. It is essential to obtain a detailed medication and illicit drug history since an estimated 25 percent of cases of erectile dysfunction may be attributable to medications for other conditions. Past medical history can reveal important causes of erectile dysfunction, including radical pelvic surgery, radiation therapy, Peyronie's disease, penile or pelvic trauma, prostatitis, priapism, or voiding dysfunction. Information regarding prior evaluation or treatment for "impotence" should be obtained. A detailed sexual history, including current sexual techniques, is important in the general history obtained. It is also important to determine if there have been previous psychiatric illnesses such as depression or neuroses.

Physical examination should include the assessment of male secondary sex characteristics, femoral and lower extremity pulses, and a focused neurologic examination including perianal sensation, anal sphincter tone, and bulbocavernosus reflex. More extensive neurologic tests, including dorsal nerve conduction latencies, evoked potential measurements, and corpora cavernosal electromyography lack normative (control) data and appear at this time to be of limited clinical value. Examination of the genitalia includes evaluation of testis size and consistency, palpation of the shaft of the penis to determine the presence of Peyronie's plaques, and a digital rectal examination of the prostate with assessment of anal sphincter tone.


Endocrine evaluation consisting of a morning serum testosterone is generally indicated. Measurement of serum prolactin may be indicated. A low testosterone level merits repeat measurement together with assessment of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prolactin levels. Other tests may be helpful in excluding unrecognized systemic disease and include a complete blood count, urinalysis, creatinine, lipid profile, fasting blood sugar, and thyroid function studies.

Although not indicated for routine use, nocturnal penile tumescence (NPT) testing may be useful in the patient who reports a complete absence of erections (exclusive of nocturnal "sleep" erections) or when a primary psychogenic etiology is suspected. Such testing should be performed by those with expertise and knowledge of its interpretation, pitfalls, and usefulness. Various methods and devices are available for the evaluation of nocturnal penile tumescence, but their clinical usefulness is restricted by limitations of diagnostic accuracy and availability of normative data. Further study regarding standardization of NPT testing and its general applicability is indicated.

After the history, physical examination, and laboratory testing, a clinical impression can be obtained of a primarily psychogenic, organic, or mixed etiology for erectile dysfunction. Patients with primary or associated psychogenic factors may be offered further psychologic evaluation, and patients with endocrine abnormalities may be referred to an endocrinologist to evaluate the possibility of a pituitary lesion or hypogonadism. Unless previously diagnosed, suspicion of neurologic deficit may be further assessed by complete neurologic evaluation. No further diagnostic tests appear necessary for those patients who favor noninvasive treatment (e.g., vacuum constrictive devices, or pharmacologic injection therapy). Patients who do not respond satisfactorily to these noninvasive treatments may be candidates for penile implant surgery or further diagnostic testing for possible additional invasive therapies.


 


A rigid or nearly rigid erectile response to intracavernous injection of pharmacologic test doses of a vasodilating agent (see below) indicates adequate arterial and veno-occlusive function. This suggests that the patient may be a suitable candidate for a trial of penile injection therapy. Genital stimulation may be of use in increasing the erectile response in this setting. This diagnostic technique also may be used to differentiate a vascular from a primarily neuropathic or psychogenic etiology. Patients who have an inadequate response to intracavernous pharmacologic injection may be candidates for further vascular testing. It should be recognized, however, that failure to respond adequately may not indicate vascular insufficiency but can be caused by patient anxiety or discomfort. The number of patients who may benefit from more extensive vascular testing is small, but includes young men with a history of significant perineal or pelvic trauma, who may have anatomic arterial blockage (either alone or with neurologic deficit) to account for erectile dysfunction.

Studies to further define vasculogenic disorders include pharmacologic duplex grey scale/color ultrasonography, pharmacologic dynamic infusion cavernosometry/ cavernosography, and pharmacologic pelvic/penile angiography. Cavernosometry, duplex ultrasonography, and angiography performed either alone or in conjunction with intracavernous pharmacologic injection of vasodilator agents rely on complete arterial and cavernosal smooth muscle relaxation to evaluate arterial and veno-occlusive function. The clinical effectiveness of these invasive studies is severely limited by several factors, including the lack of normative data, operator dependence, variable interpretation of results, and poor predictability of therapeutic outcomes of arterial and venous surgery. At the present time these studies might best be done in referral centers with specific expertise and interest in investigation of the vascular aspects of erectile dysfunction. Further clinical research is necessary to standardize methodology and interpretation, to obtain control data on normals (as stratified according to age), and to define what constitutes normality in order to assess the value of these tests in their diagnostic accuracy and in their ability to predict treatment outcome in men with erectile dysfunction.

WHAT ARE THE EFFICACIES AND RISKS OF BEHAVIORAL, PHARMACOLOGICAL, SURGICAL, AND OTHER TREATMENTS FOR IMPOTENCE? WHAT SEQUENCES AND/OR COMBINATION OF THESE INTERVENTIONS ARE APPROPRIATE? WHAT MANAGEMENT TECHNIQUES ARE APPROPRIATE WHEN TREATMENT IS NOT EFFECTIVE OR INDICATED?

General Considerations

Because of the difficulty in defining the clinical entity of erectile dysfunction, there have been a variety of entry criteria for patients in therapeutic trials. Similarly, the ability to assess efficacy of therapeutic interventions is impaired by the lack of clear and quantifiable criteria of erectile dysfunction. General considerations for treatment follow:

  • Psychotherapy and/or behavioral therapy may be useful for some patients with erectile dysfunction without obvious organic cause, and for their partners. These may also be used as an adjunct to other therapies directed at the treatment of organic erectile dysfunction. Outcome data from such therapy, however, have not been well-documented or quantified, and additional studies along these lines are indicated.
  • Efficacy of therapy may be best achieved by inclusion of both partners in treatment plans.
  • Treatment should be individualized to the patient's desires and expectations.
  • Even though there are several effective treatments currently available, long-term efficacy is in general relatively low. Moreover, there is a high rate of voluntary cessation of treatment for all currently popular forms of therapy for erectile dysfunction. Better understanding of the reasons for each of these phenomena is needed.

Psychotherapy and Behavioral Therapy

Psychosocial factors are important in all forms of erectile dysfunction. Careful attention to these issues and attempts to relieve sexual anxieties should be a part of the therapeutic intervention for all patients with erectile dysfunction. Psychotherapy and/or behavioral therapy alone may be helpful for some patients in whom no organic cause of erectile dysfunction is detected. Patients who refuse medical and surgical interventions also may be helped by such counseling. After appropriate evaluation to detect and treat coexistent problems such as issues related to the loss of a partner, dysfunctional relationships, psychotic disorders, or alcohol and drug abuse, psychological treatment focuses on decreasing performance anxiety and distractions and on increasing a couple's intimacy and ability to communicate about sex. Education concerning the factors that create normal sexual response and erectile dysfunction can help a couple cope with sexual difficulties. Working with the sexual partner is useful in improving the outcome of therapy. Psychotherapy and behavioral therapy have been reported to relieve depression and anxiety as well as to improve sexual function. However, outcome data of psychological and behavioral therapy have not been quantified, and evaluation of the success of specific techniques used in these treatments is poorly documented. Studies to validate their efficacy are therefore strongly indicated.

Medical Therapy

An initial approach to medical therapy should consider reversible medical problems that may contribute to erectile dysfunction. Included in this should be assessment of the possibility of medication-induced erectile dysfunction with consideration for reduction of polypharmacy and/or substitution of medications with lower probability of inducing erectile dysfunction.

For some patients with an established diagnosis of testicular failure (hypogonadism), androgen replacement therapy may sometimes be effective in improving erectile function. A trial of androgen replacement may be worthwhile in men with low serum testosterone levels if there are no other contraindications. In contrast, for men who have normal testosterone levels, androgen therapy is inappropriate and may carry significant health risks, especially in the situation of unrecognized prostate cancer. If androgen therapy is indicated, it should be given in the form of intramuscular injections of testosterone enanthate or cypionate. Oral androgens, as currently available, are not indicated. For men with hyperprolactinemia, bromocriptine therapy often is effective in normalizing the prolactin level and improving sexual function. A wide variety of other substances taken either orally or topically have been suggested to be effective in treating erectile dysfunction. Most of these have not been subjected to rigorous clinical studies and are not approved for this use by the Food and Drug Administration (FDA). Their use should therefore be discouraged until further evidence in support of their efficacy and indicative of their safety is available.


 


Intracavernosal Injection Therapy

Injection of vasodilator substances into the corpora of the penis has provided a new therapeutic technique for a variety of causes of erectile dysfunction. The most effective and well-studied agents are papaverine, phentolamine, and prostaglandin E[sub 1]. These have been used either singly or in combination. Use of these agents occasionally causes priapism (inappropriately persistent erections). This appears to have been seen most commonly with papaverine. Priapism is treated with adrenergic agents, which can cause life-threatening hypertension in patients receiving monoamine oxidase inhibitors. Use of the penile vasodilators also can be problematic in patients who cannot tolerate transient hypotension, those with severe psychiatric disease, those with poor manual dexterity, those with poor vision, and those receiving anticoagulant therapy. Liver function tests should be obtained in those being treated with papaverine alone. Prostaglandin E[sub 1] can be used together with papaverine and phentolamine to decrease the incidence of side effects such as pain, penile corporal fibrosis, fibrotic nodules, hypotension, and priapism. Further study of the efficacy of multitherapy versus monotherapy and of the relative complications and safety of each approach is indicated. Although these agents have not received FDA approval for this indication, they are in widespread clinical use. Patients treated with these agents should give full informed consent. There is a high rate of patient dropout, often early in the treatment. Whether this is related to side effects, lack of spontaneity in sexual relations, or general loss of interest is unclear. Patient education and followup support might improve compliance and lessen the dropout rate. However, the reasons for the high dropout rate need to be determined and quantified.

Vacuum/Constrictive Devices

Vacuum constriction devices may be effective at generating and maintaining erections in many patients with erectile dysfunction and these appear to have a low incidence of side effects. As with intracavernosal injection therapy, there is a significant rate of patient dropout with these devices, and the reasons for this phenomenon are unclear. The devices are difficult for some patients to use, and this is especially so in those with impaired manual dexterity. Also, these devices may impair ejaculation, which can then cause some discomfort. Patients and their partners sometimes are bothered by the lack of spontaneity in sexual relations that may occur with this procedure. The patient is sometimes also bothered by the general discomfort that can occur while using these devices. Partner involvement in training with these devices may be important for successful outcome, especially in regard to establishing a mutually satisfying level of sexual activity.


Vascular Surgery

Surgery of the penile venous system, generally involving venous ligation, has been reported to be effective in patients who have been demonstrated to have venous leakage. However, the tests necessary to establish this diagnosis have been incompletely validated; therefore, it is difficult to select patients who will have a predictably good outcome. Moreover, decreased effectiveness of this approach has been reported as longer term followups have been obtained. This has tempered enthusiasm for these procedures, which are probably therefore best done in an investigational setting in medical centers by surgeons experienced in these procedures and their evaluation.

Arterial revascularization procedures have a very limited role (e.g., in congenital or traumatic vascular abnormality) and probably should be restricted to the clinical investigation setting in medical centers with experienced personnel. All patients who are considered for vascular surgical therapy need to have appropriate preoperative evaluation, which may include dynamic infusion pharmaco-cavernosometry and cavernosography (DICC), duplex ultrasonography, and possibly arteriography. The indications for and interpretations of these diagnostic procedures are incompletely standardized; therefore, difficulties persist with using these techniques to predict and assess the success of surgical therapy, and further investigation to clarify their value and role in this regard is indicated.

Penile Prostheses

Three forms of penile prostheses are available for patients who fail with or refuse other forms of therapy: semirigid, malleable, and inflatable. The effectiveness, complications, and acceptability vary among the three types of prostheses, with the main problems being mechanical failure, infection, and erosions. Silicone particle shedding has been reported, including migration to regional lymph nodes; however, no clinically identifiable problems have been reported as a result of the silicone particles. There is a risk of the need for reoperation with all devices. Although the inflatable prostheses may yield a more physiologically natural appearance, they have had a higher rate of failure requiring reoperation. Men with diabetes mellitus, spinal cord injuries, or urinary tract infections have an increased risk of prosthesis-associated infection. This form of treatment may not be appropriate in patients with severe penile corporal fibrosis, or severe medical illness. Circumcision may be required for patients with phimosis and balanitis.


 


Staging of Treatment

The patient and partner must be well informed about all therapeutic options including their effectiveness, possible complications, and costs. As a general rule, the least invasive or dangerous procedures should be tried first. Psychotherapy and behavioral treatments and sexual counseling alone or in conjunction with other treatments may be used in all patients with erectile dysfunction who are willing to use this form of treatment. In patients in whom psychogenic erectile dysfunction is suspected, sexual counseling should be offered first. Invasive therapy should not be the primary treatment of choice. If history, physical, and screening endocrine evaluations are normal and nonpsychogenic erectile dysfunction is suspected, either vacuum devices or intracavernosal injection therapy can be offered after discussion with the patient and his partner. These latter two therapies may also be useful when combined with psychotherapy in those with psychogenic erectile dysfunction in whom psychotherapy alone has failed. Since further diagnostic testing does not reliably establish specific diagnoses or predict outcomes of therapy, vacuum devices or intracavernosal injections often are applied to a broad spectrum of etiologies of male erectile dysfunction.

The motivation and expectations of the patient and his partner and education of both are critical in determining which therapy is chosen and in optimizing its outcome. If single therapy is ineffective, combining two or more forms of therapy may be useful. Penile prostheses should be placed only after patients have been carefully screened and informed. Vascular surgery should be undertaken only in the setting of clinical investigation and extensive clinical experience. With any form of therapy for erectile dysfunction, long-term followup by health professionals is required to assist the patient and his partner with adjustment to the therapeutic intervention. This is particularly true for intracavernosal injection and vacuum constriction therapies. Followup should include continued patient education and support in therapy, careful determination of reasons for cessation of therapy if this occurs, and provision of other options if earlier therapies are unsuccessful.

WHAT STRATEGIES ARE EFFECTIVE IN IMPROVING PUBLIC AND PROFESSIONAL KNOWLEDGE ABOUT IMPOTENCE?

Despite the accumulation of a substantial body of scientific information about erectile dysfunction, large segments of the public -- as well as the health professions -- remain relatively uninformed, or -- even worse -- misinformed, about much of what is known. This lack of information, added to a pervasive reluctance of physicians to deal candidly with sexual matters, has resulted in patients being denied the benefits of treatment for their sexual concerns. Although they might wish doctors would ask them questions about their sexual lives, patients, for their part, are too often inhibited from initiating such discussions themselves. Improving both public and professional knowledge about erectile dysfunction will serve to remove those barriers and will foster more open communication and more effective treatment of this condition.


Strategies for Improving Public Knowledge

To a significant degree, the public, particularly older men, is conditioned to accept erectile dysfunction as a condition of progressive aging for which little can be done. In addition, there is considerable inaccurate public information regarding sexual function and dysfunction. Often, this is in the form of advertisements in which enticing promises are made, and patients then become even more demoralized when promised benefits fail to materialize. Accurate information on sexual function and the management of dysfunction must be provided to affected men and their partners. They also must be encouraged to seek professional help, and providers must be aware of the embarrassment and/or discouragement that may often be reasons why men with erectile dysfunction avoid seeking appropriate treatment.

To reach the largest audience, communications strategies should include informative and accurate newspaper and magazine articles, radio and television programs, as well as special educational programs in senior centers. Resources for accurate information regarding diagnosis and treatment options also should include doctors' offices, unions, fraternal and service groups, voluntary health organizations, State and local health departments, and appropriate advocacy groups. Additionally, since sex education courses in schools uniformly address erectile function, the concept of erectile dysfunction can easily be communicated in these forums as well.

Strategies for Improving Professional Knowledge

    • Provide wide distribution of this statement to physicians and other health professionals whose work involves patient contact.
    • Define a balance between what specific information is needed by the medical and general public and what is available, and identify what treatments are available.
    • Promote the introduction of courses in human sexuality into the curricula of graduate schools for all health care professionals. Because sexual well-being is an integral part of general health, emphasis should be placed on the importance of obtaining a detailed sexual history as part of every medical history.

 


  • Encourage the inclusion of sessions on diagnosis and management of erectile dysfunction in continuing medical education courses.
  • Emphasize the desirability for an interdisciplinary approach to the diagnosis and treatment of erectile dysfunction. An integrated medical and psychosocial effort with continuing contact with the patient and partner may enhance their motivation and compliance with treatment during the period of sexual rehabilitation.
  • Encourage the inclusion of presentations on erectile dysfunction at scientific meetings of appropriate medical specialty associations, State and local medical societies, and similar organizations of other health professions.
  • Distribute scientific information on erectile dysfunction to the news media (print, radio, and television) to support their efforts to disseminate accurate information on this subject and to counteract misleading news reports and false advertising claims.
  • Promote public service announcements, lectures, and panel discussions on both commercial and public radio and television on the subject of erectile dysfunction.

WHAT ARE THE NEEDS FOR FUTURE RESEARCH?

 

This consensus development conference on male erectile dysfunction has provided an overview of current knowledge on the prevalence, etiology, pathophysiology, diagnosis, and management of this condition. The growing individual and societal awareness and open acknowledgment of the problem have led to increased interest and resultant explosion of knowledge in each of these areas. Research on this condition has produced many controversies, which also were expressed at this conference. Numerous questions were identified that may serve as foci for future research directions. These will depend on the development of precise agreement among investigators and clinicians in this field on the definition of what constitutes erectile dysfunction, and what factors in its multifaceted nature contribute to its expression. In addition, further investigation of these issues will require collaborative efforts of basic science investigators and clinicians from the spectrum of relevant disciplines and the rigorous application of appropriate research principles in designing studies to obtain further knowledge and to promote understanding of the various aspects of this condition.

The needs and directions for future research can be considered as follows:

  • Development of a symptom score sheet to aid in the standardization of patient assessment and treatment outcome.
  • Development of a staging system that may permit quantitative and qualitative classification of erectile dysfunction.
  • Studies on perceptions and expectations associated with racial, cultural, ethnic, and societal influences on what constitutes normal male erectile function and how these same factors may be responsible for the development and/or perception of male erectile dysfunction.
  • Studies to define and characterize what is normal erectile function, possibly as stratified by age.
  • Additional basic research on the physiological and biochemical mechanisms that may underlie the etiology, pathogenesis, and response to treatment of the various forms of erectile dysfunction.

    • Epidemiological studies directed at the prevalence of male erectile dysfunction and its medical and psychological correlates, particularly in the context of possible racial, ethnic, socioeconomic, and cultural variability.
    • Additional studies of the mechanisms by which risk factors may produce erectile dysfunction.
    • Studies of strategies to prevent male erectile dysfunction.
    • Randomized clinical trials assessing the effectiveness of specific behavioral, mechanical, pharmacologic, and surgical treatments, either alone or in combination.
    • Studies on the specific effects of hormones (especially androgens) on male sexual function; determination of the frequency of endocrine causes of erectile dysfunction (e.g., hypogonadism and hyperprolactinemia) and the rates of success of appropriate hormonal therapy.
    • Longitudinal studies in well-specified populations; evaluation of alternative approaches for the systematic assessment of men with erectile dysfunction; cost-effectiveness studies of diagnostic and therapeutic approaches; formal outcomes research of the various approaches to the assessment and treatment of this condition.
    • Social/psychological studies of the impact of erectile dysfunction on subjects, their partners, and their interactions, and factors associated with seeking care.
    • Development of new therapies, including pharmacologic agents, and with emphasis on oral agents, that may address the cause of male erectile dysfunction with greater specificity.
    • Long-term followup studies to assess treatment effects, patient compliance, and late adverse effects.
    • Studies to characterize the significance of erectile function and dysfunction in women.

 


CONCLUSIONS

  • The term "erectile dysfunction" should replace the term "impotence" to characterize the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance.

  • The likelihood of erectile dysfunction increases progressively with age but is not an inevitable consequence of aging. Other age-related conditions increase the likelihood of its occurrence.
  • Erectile dysfunction may be a consequence of medications taken for other problems or a result of drug abuse.
  • Embarrassment of patients and the reluctance of both patients and health care providers to discuss sexual matters candidly contribute to underdiagnosis of erectile dysfunction.
  • Contrary to present public and professional opinion, many cases of erectile dysfunction can be successfully managed with appropriately selected therapy.
  • Men with erectile dysfunction require diagnostic evaluations and treatments specific to their circumstances. Patient compliance as well as patient and partner desires and expectations are important considerations in the choice of a particular treatment approach. A multidisciplinary approach may be of great benefit in defining the problem and arriving at a solution.
  • The development of methods to quantify the degree of erectile dysfunction objectively would be extremely useful in the assessment both of the problem and of treatment outcomes.
  • Education of physicians and other health professionals in aspects of human sexuality is currently inadequate, and curriculum development is urgently needed.
  • Education of the public on aspects of sexual dysfunction and the availability of successful treatments is essential; media involvement in this effort is an important component. This should be combined with information designed to expose "quack remedies" and protect men and their partners from economic and emotional losses.
  • Important information on many aspects of erectile dysfunction is lacking; major research efforts are essential to the improvement of our understanding of the appropriate diagnostic assessments and treatments of this condition.
  • Erectile dysfunction is an important public health problem deserving of increased support for basic science investigation and applied research.

next: Male Anorgasmia

APA Reference
Staff, H. (2009, January 3). National Institutes of Health Consensus Development Impotence Conference Statement, HealthyPlace. Retrieved on 2024, September 27 from https://www.healthyplace.com/sex/psychology-of-sex/nihc-impotence-conference-statement

Last Updated: April 9, 2016

Male Anorgasmia

sexual problems

Anorgasmia is the inability to have a climax and affects men as well as women. Another term for male anorgasmia is delayed or retarded ejaculation, which means that even after extended stimulation, the man cannot come. Estimates suggest one man in ten has this problem at some time in his life, but that only one in a hundred sees it as bad enough to need therapy.

The causes are many and complex. Clear cut reasons would include an injury or operation that blocks the nerves which are responsible for ejaculation. Less obvious is the way men are brought up, and the beliefs they have about sex. Men who, under stress, 'hold back' their climax, may be more rigid and self-disciplined in their views about sex. They may also have ideas about sex being dirty or contaminating their partner. These ideas may be conscious or unconscious, and it is possible that orgasm difficulties can occur in one situation, or with one partner, but not another.

Treatment for Male Anorgasmia

One therapeutic method calls for abstaining from intercourse, and concentrate instead on petting and cuddling. The partner is encouraged to masturbate the man to a climax outside her body.

Once the man becomes used to this, the man is asked to allow his partner to masturbate him, while he fantasizes intercourse. Very gradually, the partner is asked to masturbate the man to a climax, and then to mount him, with her on top, and to bring him to a climax in the same way. The man is encouraged at all times to fantasize about sex he had had with his partner before the problems began.

The partners are both encouraged to re-visit sexual scenarios where they had felt more liberated (eg the back of his car) and then by gradual steps, to intercourse. In this way, the man begins to bridge the gap between sex as it had always been.

In addition, the sex and relationship therapist can help the couple to identify other ways in which they could have physical fun, and help each other to let go.

The goal is to gradually begin to have intercourse on a more regular basis, with the man able to climax.


continue story below

next: Performance Anxiety

APA Reference
Staff, H. (2009, January 3). Male Anorgasmia, HealthyPlace. Retrieved on 2024, September 27 from https://www.healthyplace.com/sex/psychology-of-sex/male-anorgasmia

Last Updated: August 19, 2014

Prescription Medications Can Produce Impotency

male sexual problems

Many prescription medications can have side effects that cause erectile dysfunction (male impotence). There are about two hundred prescription medications that fall into this category. Following is a list of the most common prescription medications:

  • Antihypertensives medications:
    • beta-blockers e.g. Atenolol, Propanolol and Tenorium.
    • Diuretics medications e.g. HydroDiuril and Lasix.
    • Ace Inhibitors/Calcium Channel Blockers medications e.g. Vasotec, Lotension, Cardizem, Norvasc periodically cause erectile dysfunction (male impotence).
  • Antidepressant / Antipsychotic prescription medications of almost any label can also result in erectile dysfunction (male impotence) e.g. Prozac (Fluoxetine), Paxil (Paroxetine), Elavil (Amitriptyline), , Thorazine (Chlorpromazine), Haldol (Haloperidol). Note: Many other prescription medications in a variety of classes can periodically cause erectile dysfunction (male impotence).

    Even the newer antidepressants can cause sexual dysfunction.

  • LH-RH Analogs/Antiandrogen medications e.g. Lupron Depot®, Eulexin, Nilandron®, Casodex®, etc. These prescription medications are used in the treatment of prostate cancer. These prescription medications function by decreasing the production of testosterone in the testes and adrennal glands. The decrease in testosterone often results in erectile dysfunction (male impotence).
  • Chemotherapy/Radiation therapy for the treatment of cancer are also significant contributors to erectile dysfunction (male impotence).

NOTE: DO NOT DISCONTINUE use of prescription drugs without first verifying with your doctor.

 


 


next: Treatment for Male Impotence

APA Reference
Staff, H. (2009, January 3). Prescription Medications Can Produce Impotency, HealthyPlace. Retrieved on 2024, September 27 from https://www.healthyplace.com/sex/psychology-of-sex/prescription-medications-can-produce-impotency

Last Updated: April 9, 2016

Dr. Reid Wilson Resume

R. Reid Wilson, Ph.D.

Education

Ph.D. The Fielding Institute. Clinical Psychology. 1980. Dissertation: The Relationships Among Depression, Pain Perceptions and Therapeutic Activity in Chronic Low Back Pain Patients.

M.Ed. Antioch Graduate School. Counseling Psychology. 1977.

B.A. with Highest Honors. University of North Carolina. Sociology. 1973.

Professional Experience

July 1992 - present Department of Psychiatry, UNC School of Medicine, Chapel Hill, N.C. Clinical Associate Professor.

February 1989-December 1990 American Airlines' Achieving Flight. Psychologist.

September 1984-present Private Practice. Chapel Hill, N.C.

September 1984-1990 Clinical Hypnosis Training Program, Southeast Institute. Chapel Hill, N.C. Director.

September 1980-July 1984 Private Practice. Daniel Rutrick, M.D., P.C., Cambridge, MA.

May 1983-July 1984 Department of Psychiatry, Mt. Auburn Hospital, Cambridge, MA. Associate Staff.

January 1983-June 1981 Department of Psychiatry. Whidden Memorial Hospital, Everett, MA. Specialized Personnel.

January 1981-June 1981 Creative Living Center. West Roxbury Park Community Mental Health Center, Boston, MA. Child Therapist-intern.

August 1977-November 1979 Boston Pain Center, Massachusetts Rehabilitation Hospital, Boston, MA. Staff Psychologist.

Summer 1977 Monadnock Family and Mental Health Services. Petersborough, N.H. Therapist-intern.

September 1976-May 1977 Creamery Mental Health Office, Shelburne, VT. Therapist-intern.

September 1973-June 1976 Mental Health Project. Carolina Population Center, University of North Carolina, Chapel Hill, N.C. Training Coordinator.

October 1971-August 1973 Human Sexuality Information and Counseling Service, Chapel Hill, N.C. Founder and Director.

Certifications

Licensed Clinical Psychologist. State of North Carolina. License #1044.

Certified Consultant in Clinical Hypnosis. American Society of Clinical Hypnosis. Certificate No. 0696.

Professional Service

Anxiety Disorders Association of America. Member, Board of Directors, 1986-present.

National Conference on Anxiety Disorders. Anxiety Disorders Association of America. Chairman. 1988, 1990, 1991.

North Carolina Society of Clinical Hypnosis. President. 1985-1987.

Phobia Society of America. Southern Regional Governor. 1984-1987.

Phobia Research and Practice Journal. Founding Editorial Board Member. 1987-1995.

The Ericksonian Monographs. Founding Editorial Board Member. 1984-present.

Other Professional Organizations

American Psychological Association. Member.

North Carolina Psychological Association. Member.

Books

Foa, E.B. & Wilson, R.R. Stop Obsessing!: How to Overcome Your Obsessions and Compulsions, New York: Bantam Books, 1991.

Wilson, R.R. Don't Panic: Taking Control of Anxiety Attacks, New York: Harper & Row, 1986; Harper/Perennial Library, 1987; Revised Edition, 1996.

Wilson, R.R. (ed.) Problem Pregnancy and Abortion Counseling, Family Life Publications, Saluda, N.C., 1973.


Chapters, Articles and Booklets

Ettigi, P., Meyerhoff, A.S., Chirban, J.T., Jacobs, R.J. and Wilson, R.R. "The Quality of Life and Employment in Panic Disorder." Journal of Nervous and Mental Disease. 1997; 185(6): 368-372.

Chirban, J.T., Jacobs, J., Warren, J., Ettigi, P., Sodomsky, M. E., Clarke, J. F., Meyerhoff, A. S., Wilson, R. R., Frank, M., & Abramson, Y. M. "The 36-Item Short Form Health Survey (SF-36) and Work Productivity and the Impairment (WPAI) Questionnaire in Panic Disorder." Disease Management and Health Outcomes. 1997 Mar; 1 (3): 154-164.

Wilson, R.R. "Imaginal Desensitization," in Lindemann, Carol [ed.], Handbook of Phobia Therapy, Jason Aronson, 1989 [Revised, 1996].

Wilson, R.R. "Brief Hypnosis and Visual Rehearsals for Fearful Clients," North Carolina Journal of Mental Health, Vol. 2, No. 25, 1988.

Wilson, R.R. "A Step-wise Self-help Paradigm for Panic Disorder," Phobia Practice and Research Journal, Vol. 1, No. 2, 1988.

Wilson, R.R. "Breaking the Panic Cycle: Self-Help for People with Phobias." Rockville, MD: Anxiety Disorders Association of America, 1987. (59 page Booklet)

Wilson, R.R. "Interspersal of hypnotic phenomena within ongoing treatment," in Zeig, J. [ed.], Erickson psychotherapy: volume II, clinical applications. New York: Brunner/Mazel. 1985.

Wilson, R.R. "The Relationships Among Depression, Pain Perception and Therapeutic Activity in Chronic Low Back Pain Patients." Dissertation abstracts, 1981.

Wilson, R.R. and G.M. Arnoff. "The Therapeutic Community in the Treatment of Chronic Pain." Journal of Chronic Diseases. 32-7, 1979.

Arnoff, G.M. and R.R. Wilson. "The Therapeutic Community: A Focus for Treatment with Pain Rehabilitation Centers." Pain Abstracts: Volume One.

World Congress on Pain. 1979.Arnoff, G.M. and R.R. Wilson. "How to Teach Your Patients to Control Chronic Pain." Behavioral Medicine. 5-7, 1978.

Arnoff, G.M., R.R. Wilson and S.S. Sample. "Treating Chronic Pain: The Team Approach." Journal of Nursing Care. 11-14, 1978.

Wilson, R.R. "Sexual Counseling Skills Workshop: A Trainer's Handbook." Carolina Population Center. University of North Carolina. 1977. (77 page Booklet).

Bauman, K.E. and R.R. Wilson, "Premarital Sexual Attitudes of Unmarried University Students in 1986 and 1972," Archives of Sexual Behavior, 5-4, 1976.

Wilson, R.R. and B.A. Baldwin, "A Pilot Sexuality Training Workshop for Staff at an institution for the Mentally Retarded," American Journal of Public Health, 66-1, 1976.

Baldwin, B.A. and R.R. Wilson, "Moving from Drugs to Sex," Behavior Today, 5-48, 1974 and Psychology Today, February, 1975. (abstract).

Baldwin, B.A. and R.R. Wilson, "A Campus Peer Counseling Program in Human Sexuality," Journal of the American College Health Association, 22-5, 1974.

Bauman, K.E. and R.R. Wilson, "Contraceptive Practices of Unmarried University Students: The Significance of Four Years at One University," American Journal of Obstetrics and Gynecology, 118-2, 1974.

Wilson, R.R. Introduction to Sexual Counseling (70 page booklet), Carolina Population Center, University of North Carolina, 1974.

Wilson, R.R. Contraceptive Education: A Self-Instructional Course (booklet), Carolina Population Center, University of North Carolina, 1974.

Wilson, R.R. "The Sexual Revolution vs. the Quiet Revolution" and "Targets for Change" (chapters 13 and 14) in The Population Activist's Handbook. New York: Macmillan & Company, 1974.

Baldwin, B.A. and R.R. Wilson, "Peer Services in Human Sexuality and Health Education," Crisis Intervention, 5-3, 1974.

"Contraceptive Techniques" in Problem Pregnancy and Abortion Counseling. R.R. Wilson [ed.] Family Life Publications, Saluda, N.C., 1973.

"The Effects of Educational Stimuli on Change of Sexual Knowledge and Attitudes," Honors Thesis (Sociology), University of North Carolina, 1973.

next: Dr. Wilson as Your Anxiety Coach
~ back to Anxieties Site homepage
~ anxiety-panic library articles
~ all anxiety disorders articles

APA Reference
Staff, H. (2009, January 3). Dr. Reid Wilson Resume, HealthyPlace. Retrieved on 2024, September 27 from https://www.healthyplace.com/anxiety-panic/articles/dr-reid-wilson-resume

Last Updated: July 1, 2016

Anxiety Disorder Self-Assessment Questionnaire

Brief anxiety disorder assessment questionnaire. Define your anxiety symptoms and get immediate anxiety self-help information.Answer the following questions about your anxiety symptoms. If you check more than one question in a block, one of our free anxiety self-help programs may help you.

BLOCK 1

_____ Do you experience sudden episodes of intense and overwhelming fear that seem to come on for no apparent reason?

_____ During these episodes, do you experience symptoms similar to the following? racing heart, chest pain, difficulty breathing, choking sensation, lightheadedness, tingling or numbness?

_____ During the episodes do you worry about something terrible happening to you, such as embarrassing yourself, having a heart attack or dying?

_____ Do you worry about having additional episodes?

BLOCK 2

_____ Do you worry about a number of events or activities (such as work or school performance)?

_____ Is it difficult to control the worry.

_____ Do you also have two or more of these symptoms?

  • feeling restless or on edge
  • being easily fatigued
  • having difficulty concentrating
  • feeling irritable
  • muscle tension
  • having difficulty falling or staying asleep, or restless unsatisfying sleep

BLOCK 3

_____ Have you experienced or witnessed a frightening, traumatic event, either recently or in the past?

_____ Do you continue to have distressing recollections or dreams of the event?

_____ Do you become anxious when you face anything that reminds you of that traumatic event?

_____ Do you try to avoid those reminders?

_____ Do you have any of the following symptoms: difficulty falling or staying asleep, irritability or outbursts of anger, difficulty concentrating, feeling "on guard", easily startled?

BLOCK 4

_____ Do you have recurring thoughts or images (other than the worries of everyday life) that feel intrusive and make you anxious?

_____ On occasion, do you know that these thoughts or images are unreasonable or excessive?

_____ Do you want these thoughts or images to stop, but can't seem to control them?

_____ Do you engage in any repetitive behaviors (like hand washing, ordering, or checking) or mental acts (like praying, counting, or repeating words silently) in order to end these intrusive thoughts or images.


BLOCK 5

_____ Are you afraid of one or more social or performance situations?

  • speaking up
  • taking a test
  • eating, writing or working in public
  • being the center of attention
  • asking someone for a date

_____ Do you get anxious and worried if you try to participate in those situations?

_____ Do you avoid these situations when possible?

BLOCK 6

_____ Are you afraid on one specific object or situation, such as heights, storms, water, animals, elevators, closed-in spaces, receiving an injection, or seeing blood (excluding social situations)?

_____ Do you get anxious and worried if you try to participate in those situations?

_____ Do you avoid these situations when possible?

BLOCK 7

_____ Are you afraid of flying or a commercial airliner?

_____ Do you get anxious and worried if you fly?

_____ Do you avoid flying when possible?

BLOCK 8

_____ Are you interesting in learning more about how medications might help you manage your symptoms?

_____ Or are you currently taking a medication and wish to learn more about its benefits?

next: Panic Attacks: Introduction
~ back to Anxieties Site homepage
~ anxiety-panic library articles
~ all anxiety disorders articles

APA Reference
Staff, H. (2009, January 3). Anxiety Disorder Self-Assessment Questionnaire, HealthyPlace. Retrieved on 2024, September 27 from https://www.healthyplace.com/anxiety-panic/articles/anxiety-disorder-self-assessment-questionnaire

Last Updated: June 30, 2016

Bipolar Disorder: A Serious Psychiatric Condition

Find out about the consequences of untreated bipolar disorder including increased suicide risk, dangerous behaviors, substance abuse, not to mention the effect on loved ones.

Find out about the consequences of untreated bipolar disorder including increased suicide risk, dangerous behaviors, substance abuse, not to mention the effect on loved ones.

In spite of the fact that medications are very helpful for the treatment of most bipolar disorder patients, only one-third of bipolar disorder sufferers receive treatment. Untreated bipolar disorder opens the gate for a host of problems.

Bipolar Disorder and Risk of Suicide

It is important to note that an estimated 15% to 20% of patients who suffer from bipolar disorder and who do not receive medical attention commit suicide. The risk is greater in the following individuals:

  • In a 2001 study of bipolar I disorder, more than 50% of patients attempted suicide; the risk was highest during depressive episodes.
  • Some studies have suggested that the risk with bipolar disorder II patients is even higher than it is in patients with bipolar disorder I or major depressive disorder.
  • Patients with mixed mania, and possibly when it is marked by irritability and paranoia, are also at particular risk.
  • Many young pre- and early adolescent children with bipolar disorder are more severely ill than are adults with the disease. According to a 2001 study, 25% of children with bipolar disorder are seriously suicidal. They have a higher risk for mixed mania (simultaneous depression and mania), multiple and frequent cycles, and a long duration of illness without well periods.

Rapid cycling, although a more severe bipolar disorder variation, does not appear to increase the suicide risk for patients with bipolar disorder.

Thinking and Memory Problems in Those With Bipolar Disorder

A 2000 study reported that bipolar disorder patients had varying degrees of problems with short- and long-term memory, speed of information processing, and mental flexibility. Medications used for bipolar disorder, however, could have been responsible for some of these abnormalities and more research is needed to confirm or refute these findings.

Behavioral and Emotional Effects of Manic Phases on the Patient

A small percentage of bipolar disorder patients demonstrates heightened productivity or creativity during manic phases. More often, however, the distorted thinking and impaired judgment that are characteristic of manic episodes can lead to dangerous behavior, including the following:

  • A person may spend money with abandon, causing financial ruin in some cases.
  • Angry, paranoid, and even violent behaviors are not uncommon during a manic episode.
  • Some people are openly promiscuous.

Often such behaviors are followed by low self-esteem and guilt, which are experienced during the depressed phases. During all stages of the illness, patients need to be reminded that the mood disturbance will pass and that its severity can be diminished by treatment.

Bipolar Disorder and Substance Abuse

Cigarette smoking is prevalent among bipolar patients, particularly those who have frequent or severe psychotic symptoms. Some experts speculate that, as in schizophrenia, nicotine use may be a form of self-medication because of its specific effects on the brain; further research is necessary.

Up to 60% of patients with bipolar disorder abuse other substances (most commonly alcohol, followed by marijuana or cocaine) at some point in the course of their illness.

The following are risk factors for alcoholism and substance abuse in bipolar disorder patients:

  • Having mixed-state episodes rather than ones of pure mania.
  • Being a man with bipolar disorder.

Effects of Untreated Bipolar Disorder on Loved Ones

Patients do not work out their negative behaviors (e.g., spending sprees or even becoming verbally or physically aggressive) in a vacuum. They have a direct effect on others around them. It is very difficult for even the most loving families or caregivers to be objective and consistently sympathetic with an individual who periodically and unexpectedly creates chaos around them.

Many patients and their families, therefore, cannot admit that these episodes are part of an illness and not simply extreme, but normal, characteristics. Such denial is often strengthened by patients who are highly articulate and deliberate and can intelligently justify their destructive behavior, not only to others, but also to themselves.

Often family members feel socially alienated by the fact of having a relative with mental illness, and they conceal this information from acquaintances. (This is particularly true if the patient is female and lives away from home.) People with more education are more likely to feel ostracized by their acquaintances than are those with less education.

Economic Burden

The economic burden of bipolar disorder is significant. In 1991, the National Institute of Mental Health estimated that the disorder cost the country $45 billion, including direct costs (patient care, suicides, and institutionalization) and indirect costs (lost productivity and involvement of the criminal justice system). In spite of the obvious need for professional help, access to medical therapies is not always available for patients with bipolar disorder. In one major survey, 13% of patients had no insurance and 15% were unable to afford medical treatment.

Bipolar's Association with Physical Illnesses

Diabetes. Diabetes is diagnosed almost three times more often in people with bipolar disorder than it is in the general population. A 2002 study reported that 58% of bipolar patients were overweight, with 26% meeting the criteria for obesity. Being overweight is a significant risk factor for diabetes and so it may be the common factor in both diseases. Drugs used to treat bipolar also pose a risk for weight gain and diabetes. Common genetic factors have also been implicated in diabetes and bipolar disorder, including those causing a rare disorder called Wolfram syndrome and those that regulate carbohydrate metabolism.

Migraine Headaches. Migraines are common in patients with a number of mental illnesses, but they are particularly common among bipolar II patients. In one study, 77% of bipolar II patients had migraines while only 14% of bipolar I had this headache, suggesting that difference biologic factors may be involved with each bipolar form.

Hypothyroidism. Hypothyroidism (low thyroid levels) is a common side effect of lithium, the standard bipolar treatment. However, evidence also suggests that bipolar patients, particularly women, may be at higher risk for low thyroid levels regardless of medications. It may, in fact, be a risk factor for bipolar disorder in some patients.

For comprehensive information on bipolar disorder, visit the HealthyPlace.com Bipolar Disorder Community.

Source: NIMH Bipolar Publication. April 2008.

APA Reference
Staff, H. (2009, January 3). Bipolar Disorder: A Serious Psychiatric Condition, HealthyPlace. Retrieved on 2024, September 27 from https://www.healthyplace.com/other-info/psychiatric-disorder-definitions/bipolar-disorder-a-serious-psychiatric-condition

Last Updated: July 6, 2019

My Obsessively Clean Diary: November 2001

Quest for Freedom!

~ An insight into OCD ~ Obsessive Compulsive Disorder

Dear Diary,

I made a deal with a cigerette smoker friend. If I wash my hands excessively and for no reason, then he will smoke a cigarette!I had my birthday. It was a nice day, except it felt strange. It was my first birthday without you know who? just as this Christmas will be the first one without him. Time goes on and alas :0( it doesn't get any easier. The day felt very strange and made me feel upset towards the end of it.

I shall be seeing a psychologist in the New Year to "help me with my problem", as they put it! Other than that, I haven't got very much to say about the OCD this month!

My friend says that after Christmas we will start a deal. He wants to try and quit smoking over Christmas. Here's the deal: if I wash my hands excessively and for no reason, then he will smoke a cigarette! I'm not sure that I like the sound of that! lol, bribery and corruption is what I call it, lol.

I have done a bit of Christmas shopping, but I can't really get into it, there aren't any shops I am too scared to go into this year though, which is a huge difference of course.

Take care everyone.

Love and Hugs~Sani~

next: My Obsessively Clean Diary: January 2002
~ ocd library articles
~ all ocd related disorders articles

APA Reference
Staff, H. (2009, January 3). My Obsessively Clean Diary: November 2001, HealthyPlace. Retrieved on 2024, September 27 from https://www.healthyplace.com/ocd-related-disorders/articles/my-obsessively-clean-diary-november-2001

Last Updated: January 14, 2014